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ABBREVIATIONS 
 
1,25 (OH)2D3  1alpha,25-dihydroxyvitamin D3 IgG Immunoglobulin 
acLDL Acetylated low-density lipoprotein  IL-3 Interleukin-3 
ACLP Aortic carboxypeptidase-like protein IL-6 Interleukin-6 
ADAS cell Adipose-derived adult stem cell IMDM Isocove’s Modified Dulbecco’s Medium 
Ang Angiopoietin KCl Kalium chloride 
aP2 Adipocyte fatty acid binding protein KDR Kinase insert domain receptor 
APC Allophycocyanin KHCO3 Potassiumhydrogencarbonate Kit 
AT Adipose tissue LDL Low-density lipoprotein 
ATP Adenosintriphosphate LPL Lipoprotein lipase 
ATRA All-trans retinoic acid Mac-1 Macrophage antigen-1/CD11b 
BAT Brown adipose tissue MAP2ab Microtubule associated protein 2 a/ b 
bFGF Basic fibroblast growth factor MCP-1 Monocyte chemotactic protein-1 
BMP-2 Bone morphogenetic protein-2 M-CSF Macrophage colony-stimulating factor 
BMSC Bone marrow stem cell MMP Matrix metalloproteinases 
BSA Bovine serum albumin MOMA-2 Anti-macrophage monoclonal antibody-2 
CaCl2 Calcium chloride MS Metabolic syndrome 
CD Cluster of differentiation MSC Mesenchymal stem cell 
C/EBP CCAAT/enhancer binding protein Myf Myogenic factor 
C/EBP-α CCAAT/enhancer binding protein alfa MyoD1 Myogenic differentiation 1 
CNS Central nervous system NaCl Natrium chloride 
CO2 Carbone dioxide NAD Atrial natriuretic peptide 
CYP Cytochrome P450 NaHCO3 Sodium bicarbonate 
DAPI 4’,6’-Diamidin-2’-phenylindol-dihydrochlorid Neu N Neuronal nuclear protein 
DiI 1,1'-dioctadecyl-3,3,3',3’-tetramethylindocarbocyanine 
perchlorate 
NH4Cl Ammonium chloride 
DMEM Dulbecco’s Modified Eagle Medium NMDA N-methyl-D-aspartate 
DMSO Dimethylsulfoxid NF Neurofilament 
EC Endothelial cell NO Nitric oxide 
ECGM Endothelial Cell Growth Medium PA Plasminogen activator 
ECM Extracellular matrix PAI-1 Plasminogen activator inhibitor 1 
ED2 Anti perivascular monocytes/macrophages antibody PBS Phosphate buffered saline 
EDTA Ethylene diamine tetraacetic acid PD Population doublings 
EGF Epithelial growth factor PDGF Platelet-derived growth factor 
EGM-2 (MV) Endothelial Growth Medium 2 (Microvascular) PE Phycoerythrin 
eNOS Endothelial nitric oxide synthetase PECAM-1 Platelet endothelial cell adhesion molecule 1 
EPC Endothelial progenitor cell PFA Paraformaldehyde 
F12 Ham’s F12 PFF Pulsating fluid flow 
FA Fatty acid PLGA Poly(lactic-co-glycolic acid) 
FACS Fluorescence activated cell sorting PPARγ Pperoxisome proliferator-activated receptor gamma 
FCS Fetal calf serum PRELP Proline/arginie-rich end leucine-rich repeat protein 
FGF Fibroblast growth factor PTH Parathyroid hormone 
FITC Fluorescein-Isothiocyanat RBM Reconstituted basement membrane 
Flk-1 Fetal liver kinase 1 SCC Sideward scatter 
Flt-1 Fms like tyrosine kinase 1 SCD1 Stearoyl-CoA desaturase 
FSC Forward scatter SCF Stem cell  factor 
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GABA Gamma-amino butyric acid  SCGF-β Stem cell growth factor beta 
GFAP Glial fibrillary acidic protein SD Standard deviation 
Glut4 Glucose transporter 4 SM Smooth muscle 
GPDH Glycerol-3-phosphate dehydrogenase SMC Smooth muscle cell 
Gy Gray SSC Sideward scatter 
HDL High density lipoprotein SVF Stromal vascular fraction 
HDMEC Human dermal microvascular endothelial cell TE Tissue engineering 
HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid TGF-β Transforming growth factor beta 
hATSC Human adipose tissue stem cell TIMI-3 Thrombolysis in Myocardial Infarction 3 
hMADS cell Human multipotent adipose-derived stem cell TIMP Tissue inhibitor matrix metalloproteinases 
hTERT Human telomerase TNF-α Tumor necrosis factor alfa 
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A VCAM-1 Vascular cell adhesion molecule 1 
HNF4α Hepatocyte nuclear factor 4 alfa VE-cadherin Vascular endothelial cadherin 
hS Human autologous serum VEGF Vascular endothelial growth factor 
HSC Hematopoietic stem cell VEGF-R1 Vascular endothelial growth factor receptor 1 
HUVEC Human umbilical vein endothelial cell VEGF-R2 Vascular endothelial growth factor receptor 2 
IBMX Isobutylmethylxantine vWF Von-Willebrand factor 
ICAM-1 Intercellular adhesion molecule 1 WAT White adipose tissue 
IGF-1 Insulin-like growth factor 1   
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GERMAN SUMMARY 
 
In den letzten Jahrzehnten hat sich gezeigt, dass Fettgewebe weitaus mehr darstellt als ein 
simples Energiespeicherorgan. Es besteht neben reifen Fettzellen, sog. Adipozyten, aus 
Fettvorläuferzellen, auch Präadipozyten genannt. Präadipozyten gehören zu den mesen-
chymalen Stammzellen des Körpers und konnten das erste Mal vor mehr als dreißig Jahren 
aus humanem menschlichem Fettgewebe isoliert werden. Seither sind die Vorläuferzellen im 
Fettgewebe mehr und mehr in das Interesse der Forschung gerückt. Es ließ sich zeigen, 
dass Präadipozyten keine homogene Zellpopulation darstellen, wie anfangs geglaubt, son-
dern ganz im Gegenteil ein heterogener Mix aus verschiedenen Zelltypen sind. Die Hetero-
genität ist eine Konsequenz der Methode zur Gewinnung von Fettvorläuferzellen, nämlich 
Fettgewebsexzision oder Liposuktion. Sowohl das Herausschneiden als auch das Absaugen 
von Fett beinhaltet die Gewinnung eines ganzen Gemisches von stromalen Zellen, nicht nur 
selektiv von Fettvorläuferzellen. Die isolierten Zellen sind neben den klassischen Präadipo-
zyten auch Endothelzellen, endotheliale glatte Muskelzellen, Fibroblasten, Makrophagen und 
Blutzellen; daher spricht man auch allumfassend von der stromalen vaskulären Fraktion 
(SVF). Es hat sich gezeigt, dass sich SVF Zellen nicht nur zu reifen Adipozyten differenzie-
ren lassen, sondern auch in viele andere mesenchymale sowie nicht-mesenchymale Zellty-
pen. Die SVF des Fettgewebes gehört zu den Zellpopulationen, die sehr schwer zu charakte-
risieren sind. Daher ist die Terminologie auch nicht einheitlich. Sehr häufig finden sich neben 
dem Begriff adipose SVF Bezeichnungen wie human adipose tissue-derived stem cells oder 
adipose lineage cells. Ihre außerordentliche Differenzierungskapazität und ihre Oberflä-
chenmerkmale unterstreichen die Ähnlichkeit von SVF Zellen zu Knochenmarkstammzellen. 
Aufgrund ihrer breiten Differenzierungskapazität in meso-, ekto- und endodermale Zelltypen 
können die fettgeweblichen SVF Zellen als multipotente Stammzellen betrachtet werden.  
Neueste Forschungsergebnisse legen nahe, dass Fettgewebszellen und Endothelzellen ei-
nen gemeinsamen Zellvorläufer haben könnten. Dies wird durch die enge Beziehung zwi-
schen Angiogenese und der Entstehung von Fettgewebe unterstrichen. Angiogenese und 
Adipogenese beeinflussen sich gegenseitig; so verbessert die Interaktion zwischen Endo-
thelzellen und Adipozyten das Wachstum beider Zelltypen und bewirkt gleichzeitig eine Re-
duktion der Apoptoserate. In Hinblick auf eine gemeinsame Vorläuferzelle bleibt die For-
schung allerdings noch entscheidende Erklärungen schuldig, insbesondere der Verbin-
dungsweg zwischen Fettgewebe und Endothel, sowie das Differenzierungspotential der Zel-
len in die eine oder andere Richtung über eine gemeinsame Vorläuferzelle konnten noch 
nicht demonstriert werden. Diese Themen waren daher ein zentraler Fokus dieser Arbeit.  
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SVF Zellen wurden aus dem Fettgewebe isoliert und ihre Oberflächeneigenschaften, das CD 
(cluster of differentiation) Profil, untersucht. Für die Isolation von SVF Zellen kommen zwei 
Methoden in Frage, zum einen die Fettgewebsexzision mit anschließender Präparation der 
gewonnenen Fettgewebsläppchen oder die Liposuktion, bei der die anschließende Gewebs-
präparation entfällt. Um beide Methoden hinsichtlich ihrer Unterschiede in der Zellgewinnung 
zu vergleichen, wurden die Oberflächeneigenschaften von SVF Zellen aus exzidiertem Ge-
webe und aus liposuktioniertem Gewebe mittels Durchflusszytometrie bestimmt. Hierbei 
wurde ein besonderes Augenmerk auf endotheliale Marker sowie Stammzellmarker gelegt, 
um eventuelle Kontaminationen mit anderen Zelltypen aufzudecken. Des Weiteren wurde die 
Expression der CD Marker während einer Zellkulturphase untersucht, um Veränderungen 
der Zelloberflächeneigenschaften im Kultivierungsverlauf darzustellen. Dies ist insbesondere 
von Bedeutung, wenn SVF Zellen zur Zellvermehrung über mehrere Passagen kultiviert wer-
den und erst dann für Differenzierungsexperimente verwendet werden sollen. Das zelluläre 
CD Profil wurde neben der Durchflusszytometrie mit Hilfe von Fluoreszenzfärbungen be-
stimmt. Als endotheliale Marker wurden hauptsächlich CD31, vWF und CD105 verwendet, 
als Stammzellmarker CD34, KDR und S100. Weiterhin wurde die fettgewebliche SVF mit 
Hilfe von magnetischen Beads (Dynabeads und MicroBeads) in eine CD31+ und eine CD31- 
Fraktion aufgeteilt und die Differenzierungskapazität der jeweiligen CD31-Gruppe in Rich-
tung Fettgewebe sowie Endothel parallel untersucht. Die Differenzierung zu Endothel wurde 
mit Hilfe verschiedener Endothelzellmedien und der Kultur auf Extrazellularmatrix (Matri-
gelTM) durchgeführt. Hier wurde das Augenmerk insbesondere auf die Ausbildung kapillärer 
Strukturen auf MatrigelTM gelegt, zudem wurden die zellulären Oberflächeneigenschaften mit 
Hilfe der Durchflusszytometrie bestimmt. Die Fettzelldifferenzierung der CD31- und CD31+ 
SVF Zellen erfolgte mittels Kultivierung in einem Fettzelldifferenzierungsmedium über insge-
samt 21 Tage. Die Differenzierung wurde mit dem Glycerol-3-Phosphat Dehydrogenase 
(GPDH) Enzymassay sowie durch Öl-Rot Färbung und Zellzählung validiert.  
 
Frisch isolierte SVF Zellen aus exzidiertem Fettgewebe zeigen signifikante Unterschiede in 
ihrer Oberflächenbeschaffenheit im Vergleich zu Zellen aus Liposuktionsgewebe. SVF Zellen 
aus exzidiertem Fettgewebe sind in 5-10% positiv für CD31, die Zellen aus Liposuktionsge-
webe zeigen hingegen einen deutlich höheren Anteil an CD31 positiven Zellen von bis zu 
40%. Ähnliches gilt für KDR. Beide Zellpopulationen haben einen vergleichbaren, deutlich 
positiven Nachweis von CD34. Im Verlauf kam es bei beiden Fraktionen nach 14 Tagen in 
der Zellkultur zu einem Abfall der Stammzellmarker (CD34, KDR, S100). Um das endothelia-
le Differenzierungspotential von CD31- SVF Zellen zu evaluieren, wurden die Zellen auf Mat-
rigelTM Extrazellularmatrix in Endothelzelldifferenzierungsmedium kultiviert. Hier zeigten die 
CD31- Zellen eine ausgeprägte Tendenz, dreidimensionale, tubuläre Strukturen im Sinne 
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eines kapillären Netzwerkes auszubilden. Die Ergebnisse wurden durch die Durchflusszyto-
metrie bestätigt. Frisch isolierte SVF Zellen ohne weitere Selektierung differenzieren in vitro 
zu ca. 90% zu reifen Adipozyten. Hier wurden CD31- und CD31+ SVF Zellen im Fettzelldiffe-
renzierungsmedium kultiviert und die Ausbeute der reifen Fettzellen bestimmt. Die CD31- 
Zellfraktion differenziert zu fast 100% zu Adipozyten. Interessanterweise sind auch die 
CD31+ SVF Zellen in der Lage eine Fettzelldifferenzierung zu vollziehen, hier zeigten ca. 
65% der Zellen Lipidvakuolen. Die Bestimmung der GPDH Aktivität ergab ebenfalls einen 
Wert von 64% ± 11%, verglichen mit der GPDH Aktivität der CD31- Zellen. Während der Dif-
ferenzierung zu reifen Adipozyten trugen die CD31+ SVF Zellen weiterhin die CD31-
Dynabeads auf der Zelloberfläche.  
 
Die frisch isolierten SVF Zellen des Fettgewebes zeigen unabhängig von der Isolationsme-
thode eine starke Expression von Stammzellmarkern. Die SVF enthält jedoch auch eine Po-
pulation von CD31+ Zellen, insbesondere in Liposuktionsgewebe. Dies weist auf eine hohe 
Kontaminationsrate mit Endothelzellen in liposuktioniertem Fettgewebe im Vergleich zu exzi-
diertem Gewebe hin. Insgesamt fallen die Stammzellmarker während der Kultivierung deut-
lich ab, was wiederum in Übereinstimmung mit der Erfahrung ist, dass Präadipozyten ihre 
Differenzierungskapazität nach mehreren Passagen verlieren.  
Die Ergebnisse der endothelialen und adipogenen Differenzierung belegen, dass die fettge-
webliche SVF einen CD31- Zelltypen enthält, der zu Adipozyten sowie Endothelzellen diffe-
renziert werden kann. Zudem gibt es CD31+ Zellen, die, obwohl sie einen endothelialen Phä-
notyp besitzen, in reife Fettzellen differenziert werden können. Diese Resultate demonstrie-
ren die Fähigkeit der SVF Zellen sich in beide Richtungen, und zwar Adipozyt sowie Endo-
thelzelle, differenzieren zu können. Allgemein gesprochen zeigen die Ergebnisse die Plastizi-
tät ausgereifter, mesenchymaler Zellen aus dem Fettgewebe, eine Differenzierung zwischen 
Endothel und Fettgewebe sowie auch umgekehrt vollziehen zu können. 
Des Weiteren könnten diese Resultate von Relevanz für die Pathogenese der Arteriosklero-
se sein. Hier scheinen Transdifferenzierungsprozesse endothelialer Vorläuferzellen eine Rol-
le zu spielen.  
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SUMMARY 
 
Recent research findings postulate that adipocytes and endothelial cells (ECs) may share a 
common progenitor. However, the interlinking pathways between adipose tissue and endo-
thelium, and the differentiation potential of cells to convert from one tissue into the other via 
progenitor cells, have not been elucidated so far and are therefore the focus of this thesis. 
Stromal vascular fraction (SVF) cells were isolated from liposuction aspirates or excised adi-
pose tissue and separated into CD31+ and CD31- populations by magnet-assisted cell sort-
ing. Differentiation to fat tissue was induced in both CD31 fractions. Differentiation was as-
sayed enzymatically and by cell counting. Maturation to endothelium was performed with 
vascular endothelial growth factor, insulin like growth factor-1 plus 2% FCS and confirmed by 
flow cytometry and tube formation assays on Matrigel™. The results presented here show 
that the SVF contains a CD31-, S100+ cell type which can differentiate into adipocytes and 
EC. The SVF also comprises CD31+ cells that, although they have an endothelial phenotype, 
can be converted into mature adipocytes. These findings demonstrate the potency of SVF 
cells to perform both adipogenic and endothelial differentiation. Further, they reveal the plas-
ticity of mature cells of mesenchymal origin to undergo conversion from endothelium to adi-
pose tissue and vice versa. 
 INTRODUCTION 
 
ADIPOSE TISSUE 
 
SOURCE AND LOCATION 
In the last decades the belief was corroborated that adipose tissue is much more than a sim-
ple fat storage. Adipose tissue plays a central role in energy homeostasis and was found to 
be a highly active metabolic organ335. Many secretory factors produced by fat cells influence 
the endocrine regulation of the body, affecting growth, metabolism and behaviour. Fat tissue 
is a highly specialized connective tissue located in different places of the body and displaying 
various functions. In humans, white adipose tissue composes as much as 20% of the body 
weight in men and 25% of the body weight in women. A major portion is the subcutaneous 
fat tissue located directly underneath the dermis. Furthermore, adipose tissue is found in 
intraabdominal locations, as omental fat pads and surrounding several organs of the human 
body. Dependent on the location there are two different types of fat: white and brown adipose 
tissue. Both cushion and insulate the body, but each of them has further specialized func-
tions as well. White adipose tissue (WAT) is mainly found in the subcutaneous regions, but 
also in the Omentum Majus, lying intraabdominally between the abdominal muscles and the 
visceral organs. WAT basically functions as energy source for the body, whereas brown adi-
pose tissue (BAT) displays the heat source, primarily at young age. BAT is surrounding 
nearly all organs in the abdomen as well as in the chest. During the natural aging process 
brown fat tissue is gradually replaced by white adipose tissue. 
 
CELLULAR COMPONENTS 
The primary cellular component of adipose tissue is a collection of so called adipocytes, lipid 
filled fat cells. Focussing on the two different types of fat tissue, morphological and ultrastruc-
tural properties of brown and white adipocytes reflect the different functions in thermoregula-
tion and energy balance. White adipocytes contain only a single large fat vacuole, whereas 
brown fat cells consist of several smaller vacuoles and a much higher number of mitochon-
dria76. Brown and white adipose tissue are both innervated by the sympathetic nervous sys-
tem, which controls metabolic and lipolytic activity as well as the vascularisation in adipo-
cytes18,19.  
White mature adipocytes consist of about 90% lipids303 and each of them stands in close 
contact with at least one capillary, providing a vascular network that allows continued growth 
of the organ304. A further component located in the adipose organ is the stromal vascular 
fraction (SVF), stromal cells which are mainly located around the blood vessels. This adipose 
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SVF contains a large population of preadipocytes, first identified by Poznanski et al. in 1971 
following the enzymatic digestion of adipose tissue282,317. Preadipocytes were recently identi-
fied to have major properties of adult mesenchymal stem cells. These precursor cells are 
present troughout adult life, and differentiation into new mature adipocytes can still be 
achieved in old animals211,269.  
 
HARVESTING OF ADIPOSE TISSUE DERIVED CELLS 
A number of factors have to be taken into consideration when isolating preadipocytes or SVF 
cells from adipose tissue. Overall cell yield is determined by donor age, obesity, the anatomi-
cal site of harvest, the methods of tissue harvest, storage and preadipocyte isolation and the 
in vitro culture environment (for review158). Besides the isolation method of preadipocyte that 
defines the cell numbers harvested, the donor side exhibits a major factor for the adipogenic 
capacity of preadipocytes. In general human abdominal subcutaneous preadipocytes seem 
to have a greater potential for adipogenesis as omental or intraabdominal preadipo-
cytes150,265,384, however, other authors state that there is no difference in adipogenic potential 
between both locations352,399. In subcutaneous locations abdominal preadipocytes have a 
greater potential to convert into mature adipocytes than femoral preadipocytes146. Addition-
ally proliferation capacity in subcutaneous preadipocytes is superior to those of omental cells 
since subcutaneous cells proliferate faster under in vitro conditions399. Additionally the donor 
age plays an important role in proliferation rates of harvested cells where a negative correla-
tion can be observed between age and doubling capacity33,399. 
To release the broad spectrum of different cell types harboured in adipose tissue, minced fat 
lobules from excised tissue or plain lipoaspirate are used. The material is washed after har-
vesting to remove possible blood contamination. The extracellular matrix (ECM) holding the 
adipocytes in place is digested with collagenase solution, followed by centrifugation to divide 
mature fat cells from stromal cells. The cells located in the stromal fraction mainly appear in 
a fibroblast-like morphology after adherence to cell culture dishes, macroscopically indistin-
guishable from factual fibroblasts. At the beginning of fat tissue research these cells were 
referred to as preadipocytes or adipoblasts5,52,130, as they were found to give rise to fat vacu-
ole-containing cells. Both terms refer to fat cell precursors, but adipoblasts were regarded to 
be the juvenile adipose stem cell, contrariwise preadipocytes as the cell type in between adi-
poblast and adipocyte5. However this could not be asserted. Instead, the term preadipocyte 
was established over the last three decades and is still frequently used in the literature for 
precursor cells derived from fat tissue65,79,92,118,140,158,160,200,350,407. 
Preadipocytes are mainly located in the surrounding of small blood vessels and between 
mature fat cells in the stromal vascular fraction of fat tissue260,288,290 and can be recruited a 
lifelong6. Nevertheless, harvested adipose stromal cells display a heterogeneous cell popula-
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tion directly after isolation and are not as homogenous as initially believed. Regarding the 
isolation method of adipose stromal cells it is likely that not solely preadipocytes are digested 
from the ECM but also cells located in the blood vessels and the vessel walls. As a result the 
adipose SVF not exclusively comprises preadipocytes but also microvascular endothelial 
cells, endothelial smooth muscle cells, fibroblasts, macrophages, and blood cells (Figure 
1)427,434. 
 
SVF
preadipocytes
endothelial
cells
smooth muscle
cells
fibroblasts
macrophages
blood
cells
  
 
Major progress was made in the last few years concerning the nomenclature of the adipose 
stromal cells due to newly discovered cell features and cell characteristics158,314,433. At the 
beginning of fat tissue research the differentiation process from preadipocyte to adipocyte 
was believed to be an irreversible process, with mature fat cells as an end-stage product. In 
vitro studies, however, have demonstrated that the phenomenon of differentiation seems to 
be reversible. It has been proven in cell culture experiments that dedifferentiation of adipo-
cytes back into preadipocytes is possible281,334,430. In addition, “preadipocytes” have been 
found to be able to differentiate not only into fat cells but also into many other mesenchymal 
and non-mesenchymal cell lineages55,382,433. Further research revealed that adipose stromal 
cells have surface characteristics comparable to bone-marrow stem cells (compare Table 
1)133. Taking their remarkable differentiation potential433, these cells can be regarded as adult 
mesenchymal stem cells capable of multipotency372,388,433. 
 
MISCELLANEOUS POPULATIONS DUE TO ISOLATION AND CULTURE METHODS 
Although intensive research has been performed on fat tissue progenitor cells, the adipose 
SVF remains a cell population very hard to characterize. Consequently, in recent literature 
Figure 1. Adipose stromal 
vascular fraction (SVF)  
Freshly isolated SVF cells 
from fat tissue display a het-
erogeneous cell population 
comprising contrasting cell 
types, such as preadipocytes, 
endothelial cells, smooth mus-
cle cells, fibroblasts, blood cells 
and macrophages. 
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many different terms refer to this cell mixture isolated from adipose tissue by collagenase 
digestion. Most often these cells are called preadipocytes, but adipose tissue-derived stem 
cells113,260, adipose-derived adult stem cells23, adipose tissue mesenchymal stem cells244,382, 
multi-lineage cells from adipose tissue98, adipose tissue-derived stromal cells109,133, or adi-
pose lineage cells314 have been used to describe this population as well. Since different do-
nor sites such as abdominal, gluteal, mammary or intraabdominal fat tissue are applied for 
SVF harvesting, nonuniform populations of preadipocytes are often used for cell surface 
characterisation and differentiation assays. Consequently, literature results vary widely re-
garding the surface protein expression and the differentiation plasticity of adipose stromal 
cells.  
Two miscellaneous procedures are described for primary isolation of SVF cells, liposuction 
and plain excision during procedures, such as abdominoplasty or breast reduction. It remains 
controversial whether liposuction aspirate or excised adipose tissue displays the superior 
source for preadipocyte harvesting. Some studies state that liposuction aspirates represent a 
better source compared to excised fat405, others claim the contrary176. After excision of adi-
pose tissue (AT), fat lobules need to be isolated by removing capillaries and connective tis-
sue, a possible contamination source for endothelial cells and fibroblasts. Liposuction is per-
formed by manually applying negative pressure using a 10-cc-syringe with a blunt tip 
cannula80. Due to the harvesting procedure the isolation by liposuction damages not only AT 
but also the surrounding structures including capillaries and fibrous tissue. Therefore minced 
fat tissue from lipoaspirates contains vessels and connective tissue besides the fat compart-
ment.  
The adipose SVF harbours not only preadipocytes, but also other mature cell types, e.g. en-
dothelial cells (CD31+/CD34+), macrophages (CD14+/CD31+), and blood cells (see Figure 1). 
Certain cell fractions can be isolated with magnet-assisted cell sorting due to the expression 
of surface proteins including stem cell markers like CD34260 or kinase insert domain receptor 
(KDR)60,252, macrophage markers as CD14350, and fibroblast markers. This cell sorting can 
assist in creating a more pure and homogenous population of SVF cells by using a negative 
selection method to gain the non-labelled cells, the classical preadipocytes. 
Rodriguez et al.331 established a method to isolate two distinguishable cell populations from 
the adipose SVF based on adhesion characteristics. Cells either displayed a fast- or a slow-
adherence one. Both populations exhibited similar characteristics concerning doubling time 
(36h) and differentiation potential towards adipocytes and osteoblasts for up to 60-80 pas-
sages. After this growth period slow-adherent SVF cells ceased to proliferate and also to 
differentiate. In contrary fast-adherent SVF cells exhibited a slow proliferation rate over time 
(72h) and expressed significant levels of telomerase activity, whereas slow-adherent SVF 
cells did not. Fast-adherent SVF cells responded mainly to basic fibroblast growth factor 
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(bFGF) with expansion, but not to epithelial growth factor (EGF) or platelet-derived growth 
factor (PDGF) and could be cultured for more than 200 passages. This fast-adherent cell 
type from the adipose SVF was termed human multipotent adipose-derived stem cells 
(hMADS cells)332. 
 
ADIPOSE DERIVED ADULT STEM CELLS 
 
ADIPOSE TISSUE AS SOURCE OF MESENCHYMAL STEM CELLS 
Stem cells are defined as being qualified to distribute renewal cells for a particular mature 
cell type29. Three miscellaneous aspects delineate this special cell fraction and underline 
their uniqueness and difference from all other cell populations harboured in the human body. 
To begin with, stem cells are capable to replicate themselves leading to self-renewal and an 
extensive proliferation capacity. Second, stem cells display an immature and unspecialized 
cell type, which indicates that they do not have any tissue specificity and therefore lack spe-
cialized, tissue-specific functions. Thirdly, stem cells are able to differentiate into at least one 
specialized cell type. How many different cell phenotypes a stem cell can convert into, known 
as stem cell plasticity or potency, can be outlined with different stem cell-defining terms. 
Stem cells may be categorized as either totipotent, pluripotent, or multipotent, whereby the 
stem cell is able to form all, most, or a small number of miscellaneous cells of the body. Fur-
ther, stem cells capable of producing the blood cells of an organism are defined as hemato-
poietic stem cells. 
Several sources of stem cells were established in the past to harvest multipotent stem cells 
from lineages of the three different germinal sheets (Figure 2). According to the embryonal 
sheet and tissue location, stem cells can be classified as mesodermal, ectodermal or endo-
dermal412. Stem cells exist in humans throughout adult life in special stem cell niches418. Fur-
ther stem cells can be harvested as embryonic stem cells from the inner cell mass of the pre-
implantation blastocyst. Embryonic stem cells were isolated from either human, non-human 
primates or mice from 3-5 days old embryos43,403. Still capable of pluripotency, these cells 
have the capacity to undergo nearly the full range of differentiation pathways, including all 
three germinal lines264,318,343,359,416. Differentiation phenotypes include adipocytes, endothelial 
cells, chondrocytes, muscle cells, neuronal cells as well as blood cells and several others 
(Figure 2)43,165,236,403. However, major concerns regarding ethical topics in application of em-
bryonic stem cells in research, restrict a wider range of promising clinical usage and trials. By 
applying adult stem cells instead, most of these ethical problems can be avoided. 
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Adult stem cells, often termed mesenchymal or somatic stem cells, are mature, undifferenti-
ated cells which retained their unique capacity to differentiate into a wide spectrum of differ-
ent tissue types. They display a reserve of fibroblast-like cells that lie secluded in mature 
tissue yet can home to and repair damaged tissue when necessary219. Therefore these cells 
display an interesting source for multiple clinical applications135,258,259. Since most mesen-
chymal stem cells (MSCs) can be easily isolated, cultured and expanded, application for a 
cell-based therapy is highly attractive, e.g. the treatment of children with osteogenesis imper-
fecta168, patients with Alzheimer’s37,375,376, Parkinson’s191,394, and Crohn´s disease122, 
Duchenne muscular dystrophy332, burns321,357, cerebral ischemia193, spinal cord injuries196, 
hematopoietic recovery214, heart disease131,170,373, osteoarthritis105,327 and others. 
Mesenchymal stem cells preserve their ablility to differentiate into mature specialized cell 
phenotypes28,30,38,135,164,294,312,403 and perform self-renewal combined with maintaining their 
Figure 2. Postnatal stem and progenitor cells 
Differentiation cascade of stem and progenitor cells from mesoderm, ectoderm and endoderm. 
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specific stem cell plasticity and phenotype for several generations218. Adult stem cells com-
prise bone marrow stromal cells (BMSCs), hematopoietic stem cells (HSCs), endothelial pro-
genitor cells, as well as neural, dermal, hepatic and adipose stem cells, among others. 
Located in distinct stem cell niches in divergent tissues and organs, adult stem cells can be 
found all over the human body. One of the best known niches exists in bone marrow, har-
bouring HSCs as well as MSCs185. Additiononally multiple other sources for MSCs exist in 
the human body, including trabecular bone285, skeletal muscle428, dermis428, synovium344, 
deciduous teeth395, lung, liver, intestine, pancreas, heart35, central nervous system (CNS) 
tissue, human umbilical cord blood106,209, human placenta178, perivascular cells346 as well as 
adipose tissue209. 
Adipose tissue comprises a stromal vascular fraction comparable to the stromal fraction of 
bone marrow. SVF cells from adipose tissue have been identified as mesenchymal cells, 
being directly derived from mesenchyme, just like bone marrow433. Stromal cells from fat tis-
sue include adult mesenchymal stem cells, often referred to as preadipocytes, and in addi-
tion various other cell types as mentioned earlier98,113,434. Under stem cell supporting culture 
conditions, the SVF turns into a more homogeneous population, termed human adipose-
derived adult stem (ADAS) cells. ADAS cells have nearly equal morphology and characteris-
tics as BMSCs. Most notably they demonstrate extensive expansion potential, plasticity to 
undergo multilineage differentiation and surface protein phenotype. ADAS cells are therefore 
an alternative source for mesenchymal stem cells96,113,133,186,233,304,326,332. Additionally an ideal 
source of stem cells should be abundant, accessible and readily isolated with minimal risk to 
the patient. ADAS cells seem to outfit precisely this assortment of specifications. 
 
ADIPOSE DERIVED ADULT STEM CELLS WITH A PHENOTYPE OF BONE MARROW 
STEM CELLS 
The best known origin for mesenchymal stem cells is the stroma of bone marrow which con-
tains adult stem cells, the BMSCs. ADAS cells have been identified as mesenchymal cells as 
they are located in the stroma of adipose tissue, which is derived from mesenchyme much 
like bone marrow. Located between mature adipocytes both stem cell populations (ADAS 
cells and BMSCs) are harboured in a highly vascularised tissue with close contact to blood 
circulation.  
Not surprisingly ADAS cells exhibit a differentiation repertoire similar to that described for 
bone marrow stem cells. The cells are multipotent adult stem cells and have the ability for 
multilineage differentiation429,433,434 comprising the mesenchymal and non-mesenchymal 
branches. When cultured in vitro, ADAS cells as well as BMSCs show a fibroblast-like mor-
phology after adhering to the culture flask. Both cell types can be easily cultured and ex-
panded in vitro. Further similarities between ADAS cells and BMSCs have been described in 
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the literature focussing on growth kinetics and expansion capacity, cell senescence, gene 
transduction efficiency, gene transcription and protein surface expression. 
Noted exceptions comprise the presence of CD49d as well as the low expression of CD133, 
the lack of telomerase activity and absence of STRO-1 and CD62L on ADAS cells (Table 1). 
CD49d, STRO-1 and CD62L are thought to be molecules involved in cell homing to bone 
marrow or adipose tissue compartments. STRO-1 is expressed by stromal elements in hu-
man bone marrow and valuable for identification and functional characterisation of human 
bone marrow stromal cell precursors134. Both cell types are stromal populations isolated from 
fatty compartments based on their ability to adhere to plastic.  
It remains questionable if CD106, CD117 and ABCG2 are expressed on ADAS cells due to 
diverse reports in the literature (Table 1). 
In contrary to BMSCs lack ADAS cells the natural activity of telomerase but by transduction 
with a retrovirus containing the gene for the catalytic subunit of human telomerase (hTERT) 
stable clones can be produced and isolated188. The tranduced clones (hATSC-TERTs) have 
high telomerase activity, which could be maintained for more than 100 population doublings 
(PD). hATSC-TERTs had a normal karyotype and replicated constantly, whereas control 
cells underwent senescence-associated proliferation arrest after 36-40 PD. Supplementary 
hATSC-TERTs revealed an increased bone-forming capacity188. These results further sup-
port a similarity between BMSCs and hATSCs as studies with BMSCs demonstrated that 
telomerase expression not only extends the proliferative life-span but also maintains the os-
teogenic differentiation potential of these stem cells. 
The following table summarizes the surface expression patterns of CD markers for ADAS 
cells and BMSCs. 
 
Table 1. Characterization of adipose tissue stem cells compared to bone marrow stem cells 
Cluster of Differentiation 
Surface Expression 
Adipose Tissue 
Stem Cells 
Bone
Marrow 
Stem Cells 
Reference 
CD3 -  Strem et al. 2005 
CD4 (MHC class II co-receptor; T4) - - Katz et al., 2005, Pittenger et al., 1999 
CD8 (MHC class I co-receptor; T8) -  Katz et al., 2005 
CD9 (tetraspan) + + 
De Ugarte et al., 2003, Erickson et al., 2002, Gimble 
et al., 2003, Gronthos et al., 2001, Guilak et al., 
2006, Strem et al., 2005, Zuk et al., 2002 
CD10 (CALLA) + + 
Aust et al., 2004, De Ugarte et al., 2003, Erickson et 
al., 2002, Festy et al., 2005, Gimble et al., 2003, 
Gronthos et al., 2001, Strem et al., 2005, Zuk et al, 
2002,  
CD11 (alfa-integrin) - +/- 
Aust et al., 2004, Barry et al., 2004, Gimble et al., 
2003, Gronthos et al., 2001, Katz et al., 2005, Pit-
tenger et al., 1999, Suva et al., 2004 
CD13 (aminopeptidase) + + Aust et al., 2004, De Ugarte et al., 2003, Erickson et 
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al., 2002, Festy et al., 2005, Gimble et al., 2003, 
Gronthos et al., 2001, Mitchell et al., 2006, Planat-
Benard et al., 2004, Rodriguez et al., 2005, Strem et 
al., 2005, Talens-Visconti et al., 2006, Zuk et al., 
2002 
CD14 + low/- - 
Baksh et al., 2004, Curat et al., 2004, Gimble et al., 
2003, Gronthos et al., 2001, Jorgensen et al., 2004, 
Lee et al., 2004, Minguell et al., 2001, Miranville et 
al., 2004, Sengenes et al., 2005, Strem et al., 2005, 
Suva et al., 2004, Zuk et al., 2002 
CD15 -  Rodriguez et al., 2005, Strem et al., 2005 
CD16 -  Strem et al., 2005, Zuk et al., 2002 
CD18 (β-2 integrin) - - Gimble et al., 2003, Katz et al., 2005, Pittenger et 
al., 1999 
CD29 (β-1 integrin, fibronectin 
receptor) 
+ + 
Aust et al., 2004, Baksh et al., 2004, Cao et al., 
2005, De Ugarte et al., 2003, Erickson et al., 2002, 
Gimble et al., 2003, Gronthos et al., 2001, Guilak et 
al., 2006, Katz et al., 2005, Lee et al., 2004, Mitchell 
et al., 2006, Pittenger et al., 1999, Silva et al., 2003, 
Strem et al., 2005, Zuk et al., 2002 
CD31 (PECAM-1) + low/- - 
Curat et al., 2004, De Ugarte et al., 2003, Fraser et 
al., 2006, Gimble et al., 2003, Mitchell et al., 2006, 
Planat-Benard et al., 2004, Strem et al., 2005, Wos-
nitza et al, 2006, Zuk et al., 2002 
CD33 -  Strem et al., 2005 
CD34 (sialoumucin) +/- - 
Baksh et al., 2004, De Ugarte et al., 2003, Erickson 
et al., 2002, Festy et al., 2005, Fraser et al., 2006, 
Gimble et al., 2003, Gronthos et al., 2001, Jorgen-
sen et al., 2004, Koc et al., 2000, Lee et al., 2004, 
Minguell et al., 2001, Miranville et al., 2004, Mitchell 
et al., 2006, Planat-Benard et al., 2004, Reyes et al., 
2001, Strem et al., 2005, Suva et al., 2004, Wosnitza 
et al, 2006, Zuk et al., 2002 
CD36 +  Festy et al., 2005 
CD38 -  Strem et al., 2005 
CD41a (gpIIb) -  Katz et al., 2005 
CD44 (hyaluronate receptor or 
phagocytic glycpprotein-1) 
+ + 
Aust et al., 2004, Baksh et al., 2004, Cao et al., 
2005, De Ugarte et al., 2003, Erickson et al., 2002, 
Fraser et al., 2006, Gimble et al., 2003, Gronthos et 
al., 2001, Lee et al., 2004, Minguell et al., 2001, 
Mitchell et al., 2006, Pittenger et al., 1999, Rodri-
guez et al., 2005, Silva et al., 2003, Strem et al., 
2005, Zuk et al., 2002 
CD45 (LCA) +/- - 
Aust et al., 2004, Baksh et al., 2004, Curat et al., 
2004, De Ugarte et al., 2003, Fraser et al., 2006, 
Gimble et al., 2003, Gronthos et al., 2001, Jorgen-
sen et al., 2004, Koc et al., 2000, Lazarus et al., 
1995, Minguell et al., 2001, Miranville et al., 2004, 
Reyes et al., 2001, Strem et al., 2005, Suva et al., 
2004, Zuk et al., 2002 
CD49b (alfa-2 integrin) + + Katz et al., 2005, Pittenger et al., 1999, Rodriguez et 
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al., 2005 
CD49d (alfa-4 integrin) + - 
De Ugarte et al., 2003, Erickson et al., 2002, Fraser 
et al., 2006, Gimble et al., 2003, Gronthos et al., 
2001, Katz et al., 2005, Pittenger et al., 1999, Silva 
et al., 2003, Strem et al., 2005, Zuk et al., 2002 
CD49e (alfa-5 integrin)  + + 
Aust et al., 2004, De Ugarte et al., 2003, Erickson et 
al., 2002, Gronthos et al., 2001, Katz et al., 2005, 
Pittenger et al., 1999, Silva et al., 2003, Strem et al., 
2005, Zuk et al., 2002 
CD49f (alfa-6 integrin) -  Katz et al., 2005 
CD50 (ICAM-3) - - Gimble et al., 2003, Minguell et al., 2001 
CD51/61 (vitronectin receptor) +/- +/- 
Katz et al., 2005, Pittenger et al., 1999, Silva et al., 
2003, Wosnitza et al., 2006 
CD54 (ICAM-1) + + 
De Ugarte et al., 2003, Erickson et al., 2002, Gimble 
et al., 2003, Gronthos et al., 2001, Strem et al., 
2005, Zuk et al., 2002 
CD55 (DAF) + + 
De Ugarte et al., 2003, Erickson et al., 2002, Festy 
et al., 2005, Gimble et al., 2003, Gronthos et al., 
2001, Strem et al., 2005, Zuk et al., 2002 
CD56 (NCAM) -  
Gimble et al., 2003, Gronthos et al., 2001, Strem et 
al., 2005, Zuk et al., 2002 
CD59 (complement protein) + + 
Aust et al., 2004, De Ugarte et al., 2003, Erickson et 
al., 2002, Festy et al., 2005, Gimble et al., 2003, 
Gronthos et al., 2001, Strem et al., 2005, Zuk et al., 
2002 
CD62E (E-selectin) - - 
Gimble et al., 2003, Gronthos et al., 2001, Pittenger 
et al., 1999, Zuk et al., 2002 
CD62L (L-selectin) - + Katz et al., 2005, Pittenger et al., 1999 
CD62P (P-selectin) - - 
Katz et al., 2005, Pittenger et al., 1999, Strem et al., 
2005 
CD63 +  Mitchell et al., 2006 
CD65 +  Festy et al., 2005 
CD71 (transferrin receptor) + + 
Baksh et al., 2004, Gimble et al., 2003, Zuk et al., 
2002 
CD73 (5´nucleotidase) +  Gimble et al., 2003, Mitchell et al., 2006 
CD90 (Thy-1) + + 
Aust et al., 2004, Baksh et al., 2004, De Ugarte et 
al., 2003, Gimble et al., 2003, Jorgensen et al., 
2004, Katz et al., 2005, Lee et al., 2004, Mitchell et 
al., 2006, Pittenger et al., 1999, Rodriguez et al., 
2005, Silva et al., 2003, Strem et al., 2005, Suva et 
al., 2004, Talens-Visconti et al., 2006, Zuk et al., 
2002 
CD104 -  
Gimble et al., 2003, Strem et al., 2005, Zuk et al., 
2002 
CD105 (endoglin) + + 
Baksh et al., 2004, Cao et al., 2005, De Ugarte et 
al., 2003, Erickson et al., 2002, Fraser et al., 2006, 
Gimble et al., 2003, Gronthos et al., 2001, Guilak et 
al., 2006, Jorgensen et al., 2004, Knippenberg et al., 
2005, Lee et al., 2004, Majumdar et al., 1998, Rodri-
guez et al., 2005, Strem et al., 2005, Talens-Visconti 
et al., 2006, Zuk et al., 2002 
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CD106 (VCAM-1) +/- + 
Baksh et al., 2004, De Ugarte et al., 2003, Erickson 
et al., 2002, Fraser et al., 2006, Gimble et al., 2003, 
Gronthos et al., 2001, Gronthos et al., 2003, Jorgen-
sen et al., 2004, Katz et al., 2005, Majumdar et al., 
1998, Pittenger et al., 1999, Strem et al., 2005, Zuk 
et al., 2002 
CD117 (c-Kit) +/- + 
De Ugarte et al., 2003, Katz et al., 2005, Lee et al., 
2004, Minguell et al., 2001, Rodriguez et al., 2005, 
Strem et al., 2005, Zuk et al., 2002 
CD133/AC133 + low/- + 
Gronthos et al., 2001, Gronthos et al., 2003, Katz et 
al., 2005, Rodriguez et al., 2005, (Prentice et al., 
2004) 
CD138 (syndecan-1) +  Katz et al., 2005 
CD140a (PDGFR-alfa) + + Katz et al., 2005, Pittenger et al., 1999 
CD144 (VE-cadherin) + low/-  Mitchell et al., 2006, Strem et al., 2005 
CD146 (Muc18) + + 
De Ugarte et al., 2003, Erickson et al., 2002, Gimble 
et al., 2003, Gronthos et al., 2001, Strem et al., 
2005, Zuk et al., 2002 
CD166 (ALCAM) + + 
Aust et al., 2004, De Ugarte et al., 2003, Erickson et 
al., 2002, Gimble et al., 2003, Gronthos et al., 2001, 
Guilak et al., 2006, Knippenberg et al., 2005, Mit-
chell et al., 2006, Strem et al., 2005, Zuk et al., 2002 
CD243 (MDR-1) -  Katz et al., 2005 
ABCG2 +/- + Katz et al., 2005, Mitchell et al., 2006 
aldehyde dehydrogenase +  Mitchell et al., 2006 
alfa smooth muscle actin + + Gimble et al., 2003, Minguell et al., 2001 
Collagen I + + Gimble et al., 2003, Minguell et al., 2001 
Collagen II + + Gimble et al., 2003, Minguell et al., 2001 
Glycophorin A -  Rodriguez et al., 2005 
HLA-ABC + + 
Aust et al., 2004, Baksh et al., 2004, Barry et al., 
2004, Cao et al., 2005, Gimble et al., 2003, Katz et 
al., 2005, Planat-Benard et al., 2004, Silva et al., 
2003, Suva et al., 2004 
HLA-DR - - 
Aust et al., 2004, Barry et al., 2004, Gimble et al., 
2003, Gronthos et al., 2001, Katz et al., 2005, Lee et 
al., 2004, Rodriguez et al., 2005, Silva et al., 2003 
KDR/Flk1 (VEGF-R2) + 
 Cao et al., 2005, Mitchell et al., 2006, Wosnitza et 
al., 2006 
Osteonectin + + Gimble et al., 2003, Katz et al., 2005 
Osteopontin + + 
Gimble et al., 2003, Katz et al., 2005, Minguell et al., 
2001 
S100 + 
 Atanassova et al., 2001, Kato et al., 1988, Wosnitza 
et al., 2006 
SH3 + + 
De Ugarte et al., 2003, Koc et al., 2000, Zuk et al., 
2002 
STRO-1 +/- + 
Baksh et al., 2004, De Ugarte et al., 2003, Fraser et 
al., 2006, Gimble et al., 2003, Gronthos et al., 2001, 
Gronthos et al., 2003, Majumdar et al., 1998, Rodri-
guez et al., 2005, Strem et al., 2005, Zuk et al., 2002 
telomerase - + Katz et al., 2005 
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Vimentin + + Gimble et al., 2003, Minguell et al., 2001 
vWF low +  Mitchell et al., 2006, Wosnitza et al., 2006 
 
 
RELEVANT CD MARKERS AND THEIR EXPRESSION PATTERN 
In this thesis, the major aim was to differentiate between cells of endothelial versus adipo-
genic origin, and also to determine the level of maturation of the screened cells. Therefore, 
the following markers were selected to be applied for flow cytometry analyses. CD31, also 
known as platelet endothelial cell adhesion molecule 1 (PECAM-1), is commonly used for 
labeling endothelial cells but is also expressed by monocytes, platelets, lymphocytes, and 
granulocytes. CD51/61 labels various types of endothelial cells while vWF is expressed by 
endothelial cells and platelets. CD105, or endoglin, is expressed by endothelial cells, acti-
vated monocytes and tissue macrophages, hematopoietic progenitor cells, as well as stromal 
cells of certain tissues including bone marrow. Expression of CD105 is increased on acti-
vated endothelium in tissues undergoing angiogenesis and is a component of the TGF-beta 
receptor system in human umbilical vein endothelial cells (HUVECs). CD34 is found on he-
matopoietic stem cells, vascular endothelial cells, embryonic fibroblasts and adult nervous 
tissue. CD34 is absent on adult hematopoietic cells. VEGF signalling is performed through 
KDR or VEGF receptor 2, a receptor tyrosine kinase. KDR is expressed during vasculogene-
sis and hematopoiesis and can be found on circulating endothelial progenitor cells, mature 
vascular endothelial cells, and HUVECs. Acetylated-LDL (acLDL) can be applied to differen-
tially label endothelial progenitor cells, vascular endothelial cells, and macrophages. S100 
labels nervous tissue, skeletal and cardiac muscle, malignant melanoma cells and some 
other cell types. Additionally, it is well accepted as an early marker of adipogenesis21,199. 
 
DIFFERENTIATION CAPACITY TOWARDS MULTIPLE LINEAGES 
ADAS cells have been proven to be capable of multilineage differentiation429,433,434. As stem 
cells from adipose tissue have their origin in the mesoderm, it is no longer surprising that 
these cells can undergo different mesenchymal lineage conversions. Interestingly besides 
the classic lineage differentiation, ADAS cells are likewise capable of undergoing transdiffer-
entiation towards the non-mesenchymal branches. By differentiating into neural cells, epithe-
lium, cardiomyocytes, skeletal muscle cells and hepatocytes, these cells show a wide plastic-
ity towards the ectodermal and endodermal lineage (Figure 3 and 4).  
Clonal expansion of ADAS cells has proven that at least one part of the plasticity is situated 
in a fraction of  multipotent cells332,433. Despite pluri- and multipontent populations, fat tissue 
harbours above all bi- and unipotent stem cells, solely capable of undergoing only two or one 
differentiation pathways261,332.  
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To investigate multipotency, Rodriguez et al. created a single clone from fast-adherent ADAS 
cells and proved that two out of 12 clones were able to undergo multilineage differentia-
tion331. The remaining ten clones had bipotent capacity. In contrary to these findings Kang et 
al. found that a high percentage of single clones derived from primate ADAS cells were able 
to retain adipogenic (82%), osteogenic (64%) and neurogenic (79%) differentiation potential. 
The majority of clones (17 out of 20) showed even pluripotency along several mesodermal 
and neuronal lineages195. These findings indicate that a high percentage of ADAS cells have 
multipotential as well as pluripotential capacity in vitro due to self-renewal and creation of 
daughter cells with the potency to convert into the major mesodermal and ectodermal line-
ages. Guilak et al. found that at least 81% out of 45 human ADAS cell clones showed unipo-
tency by differentiating into adipocytes, chondrocytes, osteocytes or neuronal cells138. Fur-
ther 52% of the ADAS cell clones converted into two or more lineages. The major number of 
clones expressed phenotypes of osteoblasts (48%), chondrocytes (43%), and neuron-like 
cells (52%) than of adipocytes (12%) which could be due to the repeated doublings leading 
to the loss of adipogenic differentiation capacity amoung ADAS cells. These findings also 
support the hypothesis that ADAS cells are capable of undergoing multipotent differentiation 
pathways of the mesodermal and ectodermal lineages and do not solely consist of a mixture 
of different unipotent stem cells. However, further investigation on incidence and percentage 
between multipotent, bipotent and unipotent adipose mesenchymal stem cells remains es-
sential. 
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Figure 3. Multiple differentiation pathways of human SVF cells 
Human SVF cells convert into multiple cell lineages under appropriate culture conditions, including fat tissue, endothelial cells, 
chondrocytes, osteocytes, myocytes, epithelial cells, hepatocytes, cardiomyocytes, neuronal cells and macrophages. 
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Figure 4. Scheme of SVF cell differentiation 
SVF cells are capable to perform self-renewal and additionally to differentiate into numerous different cell types. The 
lineage-committed cell progresses through several stages of maturation prior to the onset of terminal differentiation, 
which is marked by the cessation of proliferation and shift towards increased expression of tissue-specific markers. 
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MESODERMAL DIFFERENTIATION 
 
ADIPOGENESIS 
Adipose-tissue derived adult mesenchymal stem cells naturally differentiate into mature adi-
pocytes. In adipogenic induction medium, ADAS cells develop intracellular lipid vacuoles 
which coalesce and give rise to a single, cytoplasma-filling vacuole. Besides this definite 
marker of adipogenesis349,414, several fat cell specific genes are expressed, comprising glyc-
erol-3-phosphate dehydrogenase (GPDH)216, lipoprotein lipase127,272, peroxisome proliferator-
activated receptor γ (PPARγ)366, leptin246, adipocyte fatty acid binding protein (aP2)11, 
CCAAT/enhancer binding protein (C/EBP) and glucose transporter 4 (Glut4) (Figure 5)149. 
GPDH is a key enzyme in adipose progenitor cell differentiation335 and has been widely ap-
plied for decades to measure the degree of adipocyte conversion298,368. The occurrence of 
the genes given above in ADAS derived fat cells personates a very analogical pattern to that 
noted in adipogenesis in MSCs82,308,312. 
Adipocyte conversion of ADAS cells is not exclusively mined by miscellaneous growth factors 
and the absence of serum (which acts as inhibitor during differentiation), but also by extracel-
lular matrix proteins, like fibronectin and collagen among others369.  
ADAS proliferation and differentiation are two intimately connected processes, in adipogene-
sis as well as differentiation into other cell types (compare also Figure 4). Long-term prolif-
eration in fetal calf serum (FCS)-supplemented medium notedly and irreversibly decrease 
ADAS cell potency to undergo fat differentiation149,158,160. Contrary to FCS, human autologous 
serum (hS) enables long-term proliferation as well as subsequent differentiation, even after 
prolonged culture and doubling rates160. Some studies support a composite of FCS with hS, 
due to the fact that ADAS cells cultured in hS alone were found to proliferate weekly123, did 
not attach to the culture flask75, or were not viable148. Hence the inhibitory effect of prolonged 
proliferation periods in FCS-supplemented medium is most likely due to serum factors in the 
FCS, varying between sundry charges and unpredictable to change or control. According to 
this, a serum-free culture medium would be highly desirable136,202,387. 
Optimal differentiation results are achieved when adipogenic induction medium is added at 
maximal cell confluence. Also, an age-related decrease in proliferation and differentiation 
capacity in ADAS cells has been observed7,147,198. 
 
During acquisition of the adipocyte phenotype chronological changes in the expression of 
several genes appear, including early, intermediate and late mRNA and protein markers as 
well as triglyceride accumulation (see Figure 5)57,68,247,271,286.  
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Cell confluence and cell-cell contact both improve adipocyte conversion but are not manda-
tory for fat differentiation298. Growth arrest, in contrary, appears to be inevitable for differen-
tiation of ADAS cells into mature adipocytes.  
Adipocyte specific genes are mainly transactivated by two transcription factors, PPAR-γ and 
CCAAT/enhancer binding protein α (C/EBP-α)72,93,223,366. Both of them are also involved in 
growth arrest required for adipocyte conversion. Furthermore C/EBP-α acts as an antimitotic 
agent and leads to growth inhibition390,396. PPAR-γ is capable of inducing growth arrest in 
fibroblasts and other cells, leading to cell cycle withdrawal9. PPAR-γ and C/EBP-α seem to 
act cooperatively to bring about growth arrest that precedes differentiation9.  
 
After withdrawal from the cell cycle in the early stage of adipocyte development, premature 
signs of differentiation include the expression of lipoprotein lipase (LPL) mRNA4,83,132,247,272. 
LPL is secreted in high amounts by mature fat cells and plays a central role in controlling lipid 
accumulation89,129. LPL expression is independent of the addition of adipocyte differentiation 
substrates and emerges spontaneously at cell confluence12,13. Therefore LPL occurrence 
may display growth arrest rather than an early marker of adipogenesis and is not adipocyte 
specific90,115,386. PPAR-γ and C/EBP expression is significantly upregulated during early adi-
pocyte differentiation, although low levels of these factors are also expressed in undifferenti-
ated ADAS cells. Both are subsequently involved in terminal differentiation by transactivation 
of adipocyte specific genes and maximal levels of expression are attained in mature fat 
cells54,71,72,420. During conversion into adipocytes, ADAS cells change their morphology from a 
fibroblast-like shape to a spherical appearance. This process of lipid accumulation also in-
cludes major changes in cytoskeletal components, like actin and tubulin among others88,367, 
as well  as the level and types of extracellular matrix elements276 221,277. These changes in 
cell shape reflect a distinct process in differentiation and are not results of lipid vacuole ac-
cumulation.  
 
Two major events in terminal adipogenesis are de novo lipogenesis and acquisition of insulin 
sensitivity. Lipogenic enzyme levels, including mRNA and protein expression, and activity of 
triglycerol metabolism, increase 10- to 100-fold during final differentiation into adipocytes. 
Maturation comprises mainly glycerol-3-phosphate dehydrogenase, glycerol-3-phosphate 
acyltransferase, glyceraldehydes-3-phosphate dehydrogenase, fatty acid (FA) synthase, ace-
tyl-CoA carboxylase, stearoyl-CoA desaturase (SCD1), adenosintriphosphate (ATP) citrate 
lyase and malic enzyme306,368,411. Insulin receptor numbers, insulin sensivity and glucose 
transporter levels rise as well121,224,324,337. Furthermore, total number of adrenergic receptors 
is upregulated during adipogenic differentiation, specially an increase in the β2- and the β3-
subtypes110,111,137,222. Leptin as well as aP2, an adipocyte-specific fatty acid binding protein, 
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are likewise increased during terminal adipogenesis11,40,73,246,368. PPAR-γ and C/EBP-α are 
incorporated in the coordinate activation of several of these genes, comprising leptin, aP2, 
Glut4 and SCD1 inter alia166,245,256,392,393.  
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Although mature adipocytes were thought to remain in terminal differentiation without pro-
gressing towards dedifferentiation nor re-entering mitosis410,415, several studies support the 
capacity of mature fat cells to undergo progressive dedifferentiation back to the primary 
ADAS cell type378. Dedifferentiation followed by proliferation15,378 and subsequent differentia-
tion back into adipocytes355,377,379 as well as other lineages like endothelial cells have been 
reported (Figure 4)314. A true reversion to an ADAS bi- or even multipotential cell phenotype 
could play a role in the regulation of adipocyte and endothelial cell numbers and conse-
quently adipose tissue mass. 
 
CHONDROGENESIS 
Under chondrogenic medium conditions ADAS cells establish cellular nodules that produce 
cartilage-related extracellular matrix molecules: collagen type II, VI, sulfate proteoglycans, 
e.g. chondroitin 4-sulfate and keratan sulfate, proteoglycan aggrecan and proline/ arginine-
rich end leucine-rich repeat protein (PRELP) in vitro61,103,107,175,243,291,312,414,417,433,434. Optimal 
conditions for differentiation are high density micro mass cultures supplemented with trans-
forming growth factor beta (TGF-β) and insulin, combined with dexamethasone, ascorbate-2-
phosphate, sodium pyruvate, or combined with transferrin, to name the most common possi-
bilities24,107,175,243.  
Figure 5. Adipocyte 
differentiation 
Chronological changes in 
the cellular processes and 
transcriptional cascade 
during fat cell matura-
tion. 
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ADAS cells seeded on scaffolds and subsequently implanted produce cartilage matrix in 
vivo. Chondrogenic differentiation is influenced by different cell-biomaterial interactions, de-
pendent on the material applied. The biomaterial not only influences the chondrogenic differ-
entiation but also the mechanical properties of the construct25. ADAS cells seeded onto algi-
nate carriers followed by implantation into immunodeficient mice posses prolonged synthesis 
of cartilage matrix molecules over 12 weeks107. In vivo, engineered cartilage contains ECM 
molecules such as aggrecan, collagen II and collagen VI107,243. Besides the chondrogenic 
growth factors and the ECM environment, oxygen tension also plays an important role in 
chondrogenic differentiation. As cartilage is an avascular tissue, ADAS cells possible un-
dergo hypoxia during cartilage formation in vivo. ADAS cells differentiate in both, normoxic 
as well as hypoxic environment, but hypoxia strongly reduces in vitro chondrogenesis248. 
It remains controversial whether ADAS cells or MSCs are superior for cartilage engineer-
ing98,179,279,417. However, ADAS cells seem to have a greater chondrogenic potential than 
MSCs when applied for engineering of cartilage in vitro as well as in a rabbit osteochondral 
defect model98,279. 
 
OSTEOGENESIS 
ADAS cell differentiation towards the osteogenic cell lineage is well established for in vitro  
as well as for in vivo animal tissue engineering mod-
els102,103,141,145,163,174,194,213,230,248,291,388,421,433,434. A clinical obervation is in part responsible for 
the discovery of the osteogenic differentiation capacity of ADAS cells. A rare disorder named 
“progressive osseus heteroplasia” together with the capacity of MSCs to convert into the os-
teogenic lineage led to the asssumption that ADAS cells are likewise able to differentiate into 
osteocytes36,38,53,134,142,164,179,287,297. Patients with “progressive osseous heteroplasia” develop 
calcified nodules representing normal bone which is placed at ectopic soft-tissue locations 
including subcutaneous fat depots22,197,257,356,401.  
Osteogenic induction of ADAS cells can be achieved by similar culture conditions as used in 
MSCs, including supplementation with ascorbic acid together with 1-alpha,25-
dihydroxyvitamin D3 (1,25(OH)2D3), the hormonal metabolite of vitamin D, or 
dexamethasone194,213,291. Under osteogenic differentiation medium ADAS cells are capable of 
expressing diverse genes and proteins found in the osteoblast’s phenotype: type I collagen, 
alkaline phosphatase, osteocalcin, osteonectin, osteopontin, parathyroid hormone (PTH) 
receptor, bone morphogenetic protein-2 (BMP-2), BMP-4, BMP receptors I and II, bone sialo 
protein and RunX-1141,213,291,433. Furthermore, ADAS cells exhibit a bone-like response to fluid 
shear stress in vitro, achieved with mechanical loading by pulsating fluid flow (PFF). The re-
sult is increased nitric oxide (NO) production and cyclooxygenase-2 expression213. This might 
indicate a bone-cell specific function during bone remodelling in vivo. ADAS cells are also 
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competent to generate mineralized matrix in vitro in both long term 2D or 3D osteogenic cul-
tures. 
Human ADAS cells are able to generate bone tissue in immunodeficient rodent ectopic bone 
models when seeded onto several different carrier scaffolds103,145,163,231. Furthermore these 
cells have proven to regenerate bone defects in in vivo animal models81,85,104,and even in 
humans when applied in a clinical trial for treatment of sizeable bilateral calvarial defects235. 
Due to the restricted amount of bone marrow stem cells available in the patient with calvarial 
defects, ADAS cells were applied to the defect in a single procedure together with autolo-
gous iliac crest bone and fibrin glue combined with resorbable sheets. CT-scans three 
months after the reconstruction showed new ossification as well as nearly complete calvarial 
continuity235. 
ADAS cells have a capacity for bone formation that is comparable to bone marrow MSCs. 
They maintain their osteogenic potential with aging when conferred to juvenile cells354. 
 
SKELETAL MYOGENESIS 
Cultured under appropriate myogenic medium conditions, ADAS cells undergo conversion 
into a skeletal muscle cell phenotype in vitro263,332,433. Addition of hydrocortisone, dexa-
methasone and 5-azacytidine or coculture with primary skeletal myocytes induces myocyte-
related gene expression. Upregulated are key regulatory master factors like myogenic factor 
5 (myf5), myf6, myogenic differentiation 1 (MyoD1) and myogenin232,263,433. ADAS cells also 
respond with muscle cell differentiation in a myogenic environment, as they can be incorpo-
rated into muscle fibers of mdx mice after ischemia restoring dystrophin expression signifi-
cantly101. 
Evidence exists that ADAS cells are a promising tool for restoration of muscle function in vivo 
as well. ADAS cells attached to injectable poly(lactic-co-glycolic acid) (PLGA) spheres in-
jected subcutaneously into the necks of nude mice after culture in myogenic medium, gener-
ated new muscle tissue in vivo210. When transplanted into damaged regions of rabbit skeletal 
muscle, ADAS cells increased fiber cross section area and muscle weight, resulting in sig-
nificantly raised contractile force, compared to the injured control group27. Furthermore, there 
is striking indication that ADAS cells could be useful for the treatment of Duchenne muscular 
dystrophy. When injected into the tibial and gastrocnemius muscle in dystrophin-deficient 
mdx mice, an animal model for Duchenne muscular dystrophy, these cells induced a long-
term engraftment and a high expression of human dystrophin332.  
 
CARDIOMYOGENESIS 
The use of stem cells to regenerate damaged heart tissue is advocated as the new treatment 
for heart failure secondary to heart disease or severe myocardial infarction. There are prom-
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ising results of in vitro studies achieving myocardial differentiation in ADAS cells112,124,313,320. 
When cultured in semisolid methylcellulose medium under low serum conditions and sup-
plemented with 2-mercaptoethanol, insulin, transferrin, interleukin-3 (IL-3), IL-6 and stem cell 
factor (SCF), cohesive cell groups form and display branching fibers, sharing tight connec-
tions and beating at a single rate. These cells express cardiomyocyte-specific markers in-
cluding myosin-enhancing factor 2C, sacromeric α-actinin, ventricular and atrial myosin light 
chain MLC-2v and MLC-2a, β-myosin heavy chain, atrial natriuretic peptide (NAD) and con-
nexin43 as well as connexin40313. In a murine in vivo model of acute myocardial injury, donor 
ADAS cells were injected into the intraventricular chamber instantly after application of cryo-
injury to the myocardium373. Donor ADAS cells were identified exclusively in infarct areas of 
animals treated with ADAS cells, but not in animals without myocardial damage or in the con-
trol group without cell treatment. Areas containing donor cells were positive for Heavy Chain, 
Nkx2.5 and Troponin I373. So far this is one of the first study demonstrating that ADAS cells 
have the potency both to undergo cardiomyocytic conversion and to engraft infracted myo-
cardium in vivo373. These are promising results for future application of ADAS cells in myo-
cardial infarction and other cardiovascular diseases, that are one of the leading causes for 
morbidity and mortality in western countries. 
 
IMMUNE CELLS 
Preadipocytes as well as adipocytes secrete numerous inflammatory cytokines, such as tu-
mor necrosis factor α (TNF-α), and can be activated by lipopolysaccharide binding which 
results in immunomodulatory molecule secretion56,169,207,208,242. Furthermore, PPARγ and aP2, 
initially believed to be highly specific for adipocytes, were also found in macrophages309. In-
terestingly, preadipocytes were discovered to be genomically closer related to macrophages 
than adipocytes69. Recent studies have demonstrated that ADAS cells display common func-
tional features of monocytes and macrophages by revealing specific phagocytosis activity 
including antimicrobial activity via an oxygen-dependent mechanism342. These cells likewise 
express CD80, CD86, CD45, anti perivascular monocyte/ macrophage antibody (ED2), anti-
macrophage monoclonal antibody-2 (MOMA-2), F4/80 and macrophage antigen-1 (Mac-1)/ 
CD11b69,84. In vivo transdifferentiation after grafting ADAS cells into the peritoneal cavity al-
lowed a transdifferentiation rate into macrophages of about 70% of cells69. 
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ECTODERMAL DIFFERENTIATION 
 
NEUROGENESIS 
The ability to undergo in vitro and in vivo neuronal lineage differentiation is another property 
of ADAS cells that may have impact on CNS tissue regeneration113,195,196,385. With treatment 
of different supplement combinations, ADAS cells achieve neurosphere formation when cul-
tured at high density195. Subsequent culture of the spheroid bodies on laminin leads to final 
neural differentiation195. Differentiated cells protrude extensive cell processes with a neuronal 
morphology and express neural markers, including nestin, neuronal nuclear protein (Neu N), 
neurofilament (NF) 160, microtubule associated protein 2 a/b (MAP2ab) and the mature as-
trocyte marker glial fibrillary acidic protein (GFAP)195. While nestin and NF160 belong to the 
early markers of the neuronal lineage, MAP2ab, Neu N as well as GFAP are thought to 
match with terminal conversion of ADAS cells in neurogenesis195. Several protocols exist in 
the literature to induce neurogenic conversion and achieve expression of neuronal-specific 
markers20,117,192,339,341,419,423,433. Furthermore, positive staining for functional neuronal tissue, 
comprising the neurotransmitter gamma-amino butyric acid (GABA), both subunits of the 
glutamate N-methyl-D-aspartate (NMDA) receptor and α-1 voltage gated calcium channels, 
was detected in neural differentiated ADAS cells341. Still it remains to be investigated if such 
neurons are electrically active and functional with all essential characteristics of mature CNS 
neurons364.  
So far there are a few promising in vitro studies using ADAS cells for treatment of cerebral 
ischemia, spinal cord injury as well as other neurological disorders193,196,340. ADAS cells mi-
grate into injured cerebral lesions after ischemic stroke and improve functional deficits and 
motor recovery193. When applied in a rat model of spinal cord injury, ADAS cells migrate into 
the damaged regions and significantly improve motor function after 4-5 weeks196. 
Although neurogenesis is known to occur in adult life in limited regions of the brain119,385, 
adult neuronal stem cells remain a population unattainable for clinical applications3,119. There-
fore ADAS cells display a highly promising source for cerebral injury treatment in the future. 
 
EPITHELIAL DIFFERENTIATION 
ADAS cells are known to accelerate epidermal regeneration when seeded together with 
keratinocytes in a cutaneous reconstructive model. Furthermore, ADAS cells inhibit keratino-
cyte apoptosis and induced rete ridge- and epidermal ridge-like structure formation14. Fur-
thermore ADAS cells improve dermal regeneration in full thickness skin defects and reduce 
wound contraction and subsequent scarring99. Treatment of human ADAS cells with all-trans 
retinoic acid (ATRA) initiates cytokeratin 18 expression and the formation of keratin fibers 
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indicating epithelial differentiation. As demonstrated by Brzoska et al, more than 80% of cells 
converted to an epithelial lineage cell type after incubation with ATRA55.  
 
ENDODERMAL DIFFERENTIATION 
 
HEPATOGENIC AND INTESTINAL DIFFERENTIATION 
Although primary hepatocytes, liver stem cells and bone marrow stem cells represent the 
main sources for liver regeneration, ADAS cells have recently been transdifferentiated into 
hepatocyte-like cells351. Under treatment with a cytokine mixture and dimethylsulfoxid 
(DMSO), ADAS cell conversion into the hepatic lineage was confirmed by the expression of 
albumin, α-fetoprotein, as well as functional characteristics comprising low-density lipoprotein 
(LDL) uptake and urea production. After transplantation into a hepatic injury mouse model, 
ADAS cells differentiated into hepatocytes in vivo351. Other groups applied more complex 
differentiation protocols to induce hepatic lineage differentiation in both ADAS cells and 
MSCs, again finding upregulation of several liver-markers including albumine, cytochrome 
P450 (CYP) isoenzymes, α-fetoprotein, C/EBPβ and hepatocyte nuclear factor 4 alfa 
(HNF4α), which confirmed cellular conversion into hepatocytes381-383. 
Autologous stem cell transplantation of ADAS cells has also been used for the treatment of 
Crohn’s fistula in a phase I clinical trial122. Although a phase I trial does not allow final con-
clusions about effectiveness, the results achieved appear highly promising. After inoculation 
of fistulas with autologous ADAS cells, six fistulas out of eight showed coverage with epithe-
lium at the external opening. A healing success was obtained in 75% and no adverse effects 
were observed during the follow-up period of in average 22 months122. 
 
VASCULOGENESIS AND ANGIOGENESIS 
De novo blood vessel development in the embryo comprehends two different mechanisms, 
vasculogenesis and angiogenesis. Vasculogenesis enfolds the primary vascular plexus 
formed out of the mesoderm by differentiation of angioblasts followed by the generation of 
primary blood vessels329. The fibroblast growth factor (FGF) family is crucial to conduct the 
mesoderm in forming of angioblasts as well as hemangioblasts.  Vascular endothelial growth 
factor (VEGF) and its receptor tyrosine kinase VEGF-Receptor 2 (VEGF-R2/KDR/fetal liver 
kinase 1 (flk-1)) represent a signalling system which is highly important for the differentiation 
of endothelial cells and the development of the vascular system. Specified cell adhesion 
molecules such as vascular endothelial cadherin (VE-cadherin) and platelet endothelial cell 
adhesion molecule 1 (PECAM-1/CD31), as well as mechanical forces and vascular regres-
sion with remodelling, participate in the process of endothelial cell conversion, apoptosis, and 
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succeeding angiogenesis. Branching of several capillaries and pruning of others during vas-
culogenesis leads to de novo blood vessel formation and subsequently to a mature vascular 
network. 
Following the primary vascular plexus formation, endothelial cell differentiation and prolifera-
tion cause sprouting and splitting of blood vessels with subsequent development of new cap-
illary structures, an incident called angiogenesis. Angiogenesis consists of two different 
types, sprouting angiogenesis from pre-existing capillaries and non-sprouting angiogenesis 
or intussusception. Both require VEGF as a trigger for endothelial cell proliferation and mi-
gration62,63,328. Angiogenesis is a highly complex mechanism and displays an invasive cellular 
process which is dependent on several growth factors, proteolytic enzymes, extracellular 
matrix proteins and adhesion receptors46,143,144,180. 
Primarily, it was adopted that vasculogenesis is a process constricted to embryonal devel-
opment, but recent studies proved that postnatal vasculogenesis takes place in the adult or-
ganism with the help of endothelial progenitor cells (EPCs)353. EPCs have a similar profile 
when compared to an embryonic angioblast and these stem cells respond to angiogenic 
growth factors with proliferation and migration forming in situ blood vessels via endothelial 
differentiation. They incorporate into foci of neovascularization, thereby demonstrating that 
postnatal neovascularization consists of both, angiogenesis as well as vasculogenesis16. 
 
ANGIOGENESIS IN ADIPOSE TISSUE 
The development and maturation of adipose tissue vascularity are critical to the function of 
adipose tissue87,315. In fact adipose tissue begins to develop in well vascularized regions316 
where adipocyte development is characterized by the appearance of a number of fat cell 
clusters, termed “primitive organs”. Primitive fat organs are vascular structures in presump-
tive adipose tissue with few or no fat cells and increase throughout fetal development in 
number and size. Fetal fat cell development is locally and temporarily dependent on capillary 
formation. Arteriolar development clearly precedes adipocyte differentiation in fat tissue and 
can be used to distinguish adipose tissue depots in the fetus87. Vascular development and 
endothelial cell proliferation rate seem to be fat depot-dependent as endothelial cells from 
several different rat fat depots have different replication rates after multiple passages226,227. 
 
ADIPOGENESIS AND ANGIOGENESIS 
Endothelial cells and preadipocytes share mutual developmental and autocrine as well as 
paracrine relationships. Capillary formation in fat depots emerges synchronistically within the 
early stages of adipogenesis, characterized by appearance of perivascular preadipo-
cytes152,184. Another evidence is that both endothelial cells and preadipocytes express αvβ3 
integrin and secrete plasminogen activator inhibitor-1 (PAI-1), adjusting endothelial cell and 
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preadipocyte migration in vitro86. αvβ3 integrin is critical for vasculogenesis and angiogenesis 
during development and mediates EC attachment, spreading and migration239,299. It binds 
vitronectin, fibronectin and fibrin. PAI-1 regulates smooth muscle and endothelial cell motility 
and migration through the interaction with vitronectin and its receptor (CD51/61) as well. 
Preadipocyte-derived PAI-1 production ensures organization and coordination of adipogene-
sis and angiogenesis at local levels. Therefore preadipocytes are able to migrate together 
with sprouting capillary endothelial cells in the formation of the primitive fat organ86. 
Sprouting of new blood vessels is dependent on basement membrane protein degradation422. 
The breakdown and degradation of connective tissue and basement membrane proteins be-
long to the critical phase of angiogenesis. Two major proteolytic enzymes are crucial for ex-
tracellular protein proteolysis, the matrix metalloproteinases (MMP) and the plasminogen 
activator (PA)-plasmin system239,299,310. Inhibition of MMP activity leads to reduced or blocked 
angiogenesis, indicating the implication of extracellular proteolysis in basement membrane 
degradation, cell migration and ECM invasion, capillary lumen formation, regulation of cyto-
kine activity, and release of membrane bound VEGF and TNFα310,311.  
MMP-2 and MMP-9 as well as their tissue inhibitors (TIMP) are expressed by ADAS cells 
and adipose tissue in a depot-dependent manner51,70,100,120,251. MMP and TIMP significantly 
influence adipose tissue development by adipocyte differentiation but may do so in coopera-
tion or independent of angiogenesis51,70,88,240. 
Preadipocytes secrete PAI-1 in a depot-dependent manner32. PAI-1 inhibits both plasmino-
gen activators, t-PA and u-PA, and influences the migration of endothelial cells, smooth 
muscle cells, and preadipocytes themselves86,311. Additionally, hypoxia induces PAI-1 ex-
pression in endothelial cells311. Elevated PAI-1 levels in the circulation are involved in the 
development of the metabolic syndrome with insulin resistance and increased risk for cardio-
vascular disease8. Glitazones (insulin sensitizer) reduce human fat PAI-1 secretion leading to 
improved endothelial function in chronic cardiovascular disease states300. 
Both VEGF and FGF act as mitogenic agents in endothelial cells and preadipocytes by pro-
moting cell proliferation, migration and pericellular proteolysis (Figure 6). Their interaction on 
angiogenesis is closely linked together41,389,422. VEGF acts through two tyrosine kinase recep-
tors, VEGFR-1 (fms like tyrosine kinase 1 (flt-1)) and VEGFR-2 (flk-1/KDR), which are mainly 
expressed by endothelial cells, endothelial and hematopoietc progenitor cells and mono-
cytes. VEGF and its receptors both influence EC proliferation, migration, tubulogenesis, sur-
vival, vascular permeability, MMP proteinases, and the PA system. However, it seems to be 
primarily VEGFR-2 which is crucial for angiogenesis. Besides, this receptor can be upregu-
lated in ECs by bFGF supplementation, indicating the synergism between these two growth 
factors389. FGF may play a role in angiogenesis during tissue repair299 and enhances adipo-
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cyte differentiation in vivo203. VEGF gene expression is influenced by a number of factors, 
comprising hypoxia, insulin, growth factors and several different cytokines239. 
VEGF is considered to be the major factor of the angiogenic activity of media conditioned by 
adipocytes and adipose tissue432. Fat tissue expression and secretion of VEGF is induced by 
hypoxia as well as insulin255,432. Vice versa insulin may be involved in increased adipose tis-
sue VEGF expression during rebound weight gain after diet restriction in rabbits268. Angio-
poietin (Ang)-1, Ang-2, and Tie 1 and Tie 2 receptors are regarded VEGF’s most fundamen-
tal partners (compare Figure 6)299,422. Ang-1 stabilizes blood vessel walls, whereas Ang-2 
promotes destabilization. Hypoxia, VEGF, FGF, and cytokines induce Ang-2 expression in 
microvascular ECs249,292. Several other studies have demonstrated the possibility that leptin 
induces angiogenesis or influences angiogenic factors50,59,128,187,220,289,319,358,374,431. Both adi-
pose tissue and endothelial cells express the receptor for leptin binding49,50 and leptin is pro-
duced and secreted by adipocytes. Adipose tissue leptin and VEGF expression are similarly 
regulated by hypoxia and insulin10,422. Therefore, leptin may potentiate VEGF-mediated an-
giogenesis by indirectly influencing VEGF secretion and uptake by endothelial cells302.  
Several other growth factors are involved in angiogenesis as well, e.g. PDGF-β, TGF-β, TNF-
α and FGF, promoting vessel wall stability, establishing the integrity of capillary walls during 
sprouting, and promoting tube formation in ECs (Figure 6)299,322. 
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Strong evidence suggests adipogenesis to be influenced by angiogenesis and vice 
versa338,358,360. Adipocyte endothelial cell interaction is thus presumed to be involved in the 
development and maintenance of fat tissue. Also, adipose tissue itself is an origin of several 
different vasoactive factors116. A close evolutionary relationship between preadipocytes and 
ECs can be assumed since preadipocytes have been demonstrated to influence EC prolif-
eration, reduce apoptosis325, and increase mature EC viability and migration274. Impact on 
proliferation and subsequent enhancement of tube formation, mainly meditated by secretion 
of VEGF, TGF-β, bFGF and HGF by preadipocytes48,77,274,275,325. The expression of 
leptin50,358, Ang 1370, Ang 278,139 and PAI-1345,365 by adipose tissue also has impact on angio-
genesis, as mentioned above, and the activity of these factors is interrelated. Leptin for in-
stance induces the expression of Ang 278 and enhances VEGF-mediated angiogenesis59. 
Furthermore, preadipocytes are able to increase the amount of VEGF under hypoxia325 and 
during fat pad development280. However, not exclusively adipocyte precursors are capable of 
Figure 6. Regulation of blood vessel morphogenesis 
during neovascularisation 
New vessels arise from pre-existing capillaries and post-
capillary venoles. Pericytes start to migrate and blood 
vessels dilate. Afterwards the basal membrane and the 
extracellular matrix is degraded. Now endothelial migrate 
into the perivascular space along the angiogenic stimulus 
mediated through VEGF and its receptors, VEGF recep-
tor 1 and 2. Endothelial cells begin to proliferate and form 
capillary-like structures including a lumen. TGF-β, FGF 
and PDGF function as angiogenic growth factors as well. 
FGF and VEGF function as mitogenic agents in ECs by 
promoting cell proliferation, migration and pericellular 
proteolysis. PDGF possesses a structural affinity with 
VEGF. Ang-1 navigates the interaction between endothe-
lial cells and smooth muscle cells as well as pericytes by 
stabilising the freshly formed blood vessels and acting as 
an anti-permeability factor.  
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enhancing angiogenesis. Mature adipocytes also produce significant amounts of VEGF66. 
MMP-9 which is upregulated in differentiated adipocytes51,204 increases the availability of ma-
trix-bound VEGF39. These findings indicate that mature fat cells, which require a very in-
tensely branched vascular network with direct contact to ECs, mediate endothelial cell ex-
pansion, migration and tube formation by VEGF secretion to optimize their oxygen supply 
(Figure 7). This is supported by the fact that fat cells have a significant lower tolerance for 
hypoxic conditions than preadipocytes and require higher concentration of oxygen406.  
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Reciprocally, arteriolar differentiation precedes adipocyte development during fetal fat pat 
formation87,151,154. Endothelial cell ECM maturation precedes differentiation of adipocyte 
ECM87,153,156 and endothelial cells release ECM components that enhance preadipocyte dif-
ferentiation402. Remodelling of ECM components is important for both adipogenesis241 and 
angiogenesis64. Preadipocyte spreading and migration during adipogenesis may be en-
hanced or even induced by blood vessel differentiation155. As VEGF expression can be gen-
erated by cold exposure in BAT18,19 and increased adipogenesis is promoted by enhanced 
VEGF expression during rebound weight gain after diet restriction268, angiogenesis also 
seems to play a crucial role in postnatal adipogenesis. Furthermore extracellular proteolysis 
may be able to adjust fat tissue angiogenesis as well as fat cell maturation and develop-
ment167,267. Fat tissue proliferation is dependent on angiogenesis and can be regulated 
through adipose tissue vascularization338. Anti-angiogenic agents leading to weight loss in 
mice, as demonstrated by obesity models338, and are further proof of the close relationship 
between endothelium and fat tissue. Several in vitro studies abet these findings, as ECs 
Figure 7. Adipose angio-
genesis 
Tissue hypoxia enhances 
preadipocyte and adipocyte 
secretion of proangiogenic 
factors. VEGF, FGF, TGF-β 
together with other cyto-
kines increase capillary 
formation through EC 
sprouting and Ang-1 ex-
pression. TIMP, MMP, 
PAI-1 further support 
vessel growth by tissue 
proteolysis and tube forma-
tion.   
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promote adipose tissue derived precursor cell proliferation in conditioned medium177. Direct 
adhesion of ECs promotes the active development of immature preadipocytes together with 
increased growth of mature adipocytes15. These findings support the view that endothelium 
closely regulates adipose tissue growth and homeostasis.  
 
In conclusion, modulating the development of the vascular network in adipose tissue in either 
an anti-angiogenic or pro-angiogenic manner may provide a strategy to solve problems with 
obesity and cardiovascular complications on the one hand67, on the other hand may help 
finding solutions for soft tissue engineering approaches to reconstruct defects after trauma or 
tumor removal.  
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STUDIES 
 
In this thesis, the differentiation plasticity and capacity of stromal vascular fraction cells to-
wards adipogenic and endothelial lineage was analyzed. The study was divided into the fol-
lowing six tasks: 
 
1. Comparison of SVF cells from excised fat tissue versus liposuction material 
2. Analysis of surface protein expression in SVF cells during the culturing process 
3. Differentiation of unpurified SVF cells under endothelial medium conditions 
4. Splitting of SVF cells in CD31- and CD31+ SVF cells and characterisation of purified frac-
tions 
5. Differentiation potential of CD31- and CD31+ SVF cells towards the endothelial lineage 
6. Differentiation potential of CD31- and CD31+ SVF cells towards the adipogenic lineage 
 
 
1. Comparison of SVF cells from excised fat tissue versus liposuction material 
Two distinct isolation methods for gaining cells from the adipose SVF are established in the 
literature, one from excised fat tissue and one from liposuction aspirates. Due to the harvest-
ing procedure liposuction material does not exclusively contain AT but also blood vessels 
and fibrous tissue. Isolation of SVF cells from excised AT, in contrast, involves the manual 
removal of capillaries and fibrous tissue. In order to prescind the differences in heterogenity 
between SVF cells isolated from liposuctioned versus excised AT, freshly harvested SVF 
cells from both isolation methods were analysed with flow cytometry. To quantify the amount 
of endothelial cells, hematopoietic stem cells, and other cells contained in the two cell frac-
tions, antibodies against CD31, CD51/61, CD34 and KDR were applied. 
 
2. Analysis of surface protein expression in SVF cells during the culturing process 
Not only the harvesting method but also the culture conditions influence the SVF cell charac-
teristics and their heterogenity. Long-term culturing of SVF cells generates high cell numbers 
but changes major preadipocyte characteristics, i.e. protein surface expression and differen-
tiation capacity.  
To analyse the changes in surface protein expression during culture of SVF cells in standard 
medium, flow cytometry analyses were performed with stem cell markers for CD34, KDR and 
S100 after 7 and 14 days.  
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3. Differentiation of unpurified SVF cells under endothelial medium conditions 
Usually, the harvested SVF is contaminated with ECs. When measuring preadipocyte trans-
differentiation potential to ECs, ECs embodied in the isolated SVF can mimic a successful 
differentiation result even though ECs were already present in the applied cell fraction before 
differentiation induction. To determine the growth potential of contaminating endothelial cells 
after isolation, various growth media were tested including different EC supporting media 
(EC-1, -2, -3). These culture media included standard EC media frequently used in the litera-
ture. 
The first culture medium (EC-1) applied was an endothelial lineage differentiation medium for 
angiogenic progenitor cells and contained Endothelial Growth Medium-2 Microvascular 
(EGM-2MV) with 10 ng/ml VEGF and 10-6 mol/l rosiglitazone. The second medium (EC-2), an 
endothelial differentiation medium, was Endothelial Cell Growth Medium (ECGM) supple-
mented with 50 ng/ml VEGF, 20 ng/ml IGF-1, and 2% FCS. The third culture medium (EC-3) 
tested was a hematopoietic and endothelial progenitor cell medium for peripheral blood pro-
genitor cells containing IMDM, 50 ng/ml VEGF, 100 ng/ml SCGF-ß, 30% FCS, 1% BSA, and 
10-4 mol/l ß-mercaptoethanol. 
 
4. Splitting of SVF cells in CD31- and CD31+ SVF cells and characterisation of purified frac-
tions 
In order to seperately investigate the differentiation potential of both CD31- and CD31+ SVF 
cells towards the adipogenic and endothelial lineage, splitting with paramagnetic beads was 
performed (see studies 5. and 6.). To confirm the purity of both separated cell fractions, flow 
cytometry analyses for CD105, vWF, CD34 and S100 were carried out in addition to vWF 
immunofluorescence staining and histological evaluation. HUVECs were used as positive 
control, fibroblasts as negative control. 
 
5. Differentiation potential of CD31- and CD31+ SVF cells towards the endothelial lineage 
To investigate the differentiation potential of CD31- and CD31+ SVF cells towards the endo-
thelial lineage two endothelial differentiation media (EC-2 and EC-3) were applied to both 
CD31 fractions separately. Endothelial differentiation was determined by (i) Matrigel assays 
and (ii) flow cytometry analyses. 
 
6. Differentiation potential of CD31- and CD31+ SVF cells towards the adipogenic lineage 
Both cell fractions, CD31- and CD31+ SVF cells, were tested for their differentiation potential 
towards adipose tissue. After magnetic-assisted separation SVF cells were cultured in adi-
pogenic differentiation medium. Fat cell differentiation was measured (i) on a molecular level 
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by obtaining the GPDH activity and (ii) by cell counting under light microscopy and Oil Red O 
Staining. 
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MATERIAL AND METHODS 
 
TECHNICAL EQUIPMENT 
♦ CO2 incubator, 37°C with 5% CO2 
and > 95% humidity (Heraeus) 
♦ Laminar flow hood  (Flow Laborato-
ries GmbH) 
♦ Laborwaage/ Laboratory scale (Sar-
torius) 
♦ Laborfeinwaage/ Laboratory preci-
sion scale (Sartorius basic) 
♦ Centrifuge Minifuge (T-Heraeus) 
♦ Laboratory centrifuge (SIGMA) 
♦ Centrifuge Biofuge A (Heraeus) 
♦ Phasecontrast microscope, Telaval 
31 (Zeiss) 
♦ Photo device (Nikon D100) 
♦ Fluorescence microscope Axioscope 
(Leica) 
♦ Programme DISCUS (Leica) 
♦ Coverplates (Shandon) 
♦ Counting cell chamber (Neubauer 
improved) 
♦ Water shaking bath (GFL 
1092/1083) 
♦ Shaking device Reax 2000 
(Heidolph) 
♦ Autoclave (Melag Autoklav 23) 
♦ Conical tubes, 10 ml, 50 ml konisch 
(Costar) 
♦ Pipetting device Pipetboy 
(Tecnomara) 
♦ Culture flask T-25 (25 cm2/ 5 ml) 
(Greiner) 
♦ Culture flask  T-75 (75 cm2/ 25 ml) 
(Greiner) 
♦ Culture dish/ plate, 6-well, 12-well, 
24-well, 96-well (Falcon) 
♦ Petri dish Ø 150 mm (Falcon) 
♦ Glass vials 50 ml, 100 ml, 250 ml, 
500 ml (Schott Duran) 
♦ Pipettes, 1 ml, 2 ml, 5 ml, 10 ml, 25 
ml (Greiner) 
♦ Eppendorf cups 1.5 ml (Eppendorf) 
♦ Disposable syringe Discardit II 5 ml, 
10 ml, 20 ml (Becton Dickinson) 
♦ Elisa-Reader with HP-Printer (Dynex 
Technologies) 
♦ Programme Revelation (Dynex 
Technologies) 
♦ Multi-channel pipette (Eppendorf) 
♦ Repeater Pipette and combitips (Ep-
pendorf) 
♦ Glass cylinder, Borosilikatglas 
(Braun) 
♦ Teflon flask (Braun) 
♦ Syringe driven filter unit Millex GP 
0.22 µm (Millipore) 
♦ 70 μm nylon mesh (Verseidag 
Techfab GmbH) 
♦ 250 µm nylon mesh (Verseidag 
Techfab GmbH) 
♦ Sucking device Vacusafe (IBS In-
tegra Biosciences) 
♦ Pasteurpipettes, 230 mm (Brand) 
♦ Tweezers (Aesculap) 
♦ Scalpels (Feather) 
♦ Scissors (Aesculap) 
♦ Clamps (Aesculap) 
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♦ Needles Microlance (Becton Dickin-
son) 
♦ Glass slides (Engelbrecht) 
♦ Quadriperms (Heraeus) 
♦ Magnetic rack Dynal MPC-1 (Dynal 
Biotech GmbH) 
♦ MiniMACS separation unit (Miltenyi 
Biotec GmbH) 
♦ MACS Multi Stand (Miltenyi Biotec 
GmbH) 
♦ MACS columns type MS (Miltenyi 
Biotec GmbH) 
♦ FACS Calibur apparatus (Beckton 
Dickinson)  
♦ FACS tubes (Sarstedt) 
♦ Programme Cell Quest Pro (Beckton 
Dickinson) 
♦ Parafilm (Pechiney Plastic Packing) 
 
 
 
REAGENTS 
♦ Dulbecco´s Modified Eagle Medium 
(DMEM)/Ham’s F12 (F12) 1:1 (PAA) 
♦ Dulbecco´s Modified Eagle Medium 
(DMEM) High Glucose (PAA) 
♦ Isocove´s Modified Dulbecco´s Me-
dium (IMDM) with GlutaMAX (Invi-
trogen) 
♦ Endothelial Cell Growth Medium with 
supplement mix (PromoCell) 
♦ Endothelial Growth Medium-2 Mi-
crovascular (EGM-2 MV) with sup-
plement mix (Cambrex Bio Science) 
♦ Penicillin (PAA Laboratories) 
♦ Streptomycin (PAA Laboratories) 
♦ Fetal calf serum (FCS) (Biochrom) 
♦ Bovine serum albumin (BSA) (PAA) 
♦ BSA for immunhistology (Sigma) 
♦ Basic fibroblast growth factor (bFGF) 
(Peprotech) 
♦ Vascular endothelial growth factor 
(VEGF) (Peprotech) 
♦ Insulin-like growth factor 1 (IGF-1) 
(Peprotech) 
♦ Stem cell growth factor beta (SCGF-
β) (Peprotech) 
♦ Dexamethasone (Sigma) 
♦ Insulin (Roche) 
♦ Transferrin (Sigma) 
♦ Triiodo-L-thyronine (Sigma) 
♦ Isobutylmethylxanthine (IBMX) 
(Sigma) 
♦ Pioglitazone (Takeda Pharmaceuti-
cals) 
♦ Rosiglitazone (Cayman Chemical) 
♦ Phosphat buffered saline (PBS2-) 
(Biochrom) 
♦ Aqua ad injectabile (Delta Select) 
♦ Aqua bidest (Pharmacy RWTH 
Aachen) 
♦ Trypsin 0.02%, 0.05% EDTA in PBS 
(PAA Laboratories) 
♦ Collagenase CLS Typ I (Biochrom) 
♦ Dispase Typ II (Roche) 
♦ Fibronectin (Biochrom) 
♦ Matrigel™, growth factor reduced 
(BD Biosciences) 
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♦ Cell recovery solution (BD Biosci-
ences) 
♦ Oil Red O (Merck) 
♦ Glycerol-3-phosphat-dehydrogenase 
(GPDH) activity assay kit (TaKaRa) 
♦ HEPES (Sigma Aldrich Chemie) 
♦ NaCl (Merck) 
♦ CaCl2 (Merck)  
♦ HCl (Merck) 
♦ Glucose (Merck) 
♦ NH4Cl (Merck) 
♦ NaHCO3 (Merck) 
♦ KHCO3 (Merck) 
♦ β-mercaptoethanol (Fluka) 
♦ Paraformaldehyde (PFA) (MERCK) 
♦ Acetone (Pharmacy RWTH Aachen) 
♦ 4’,6’-Diamidin-2’-phenylindol-
dihydrochlorid (DAPI) (Boehringer 
Mannheim) 
♦ DAPI working solution (10µl DAPI 
stock solution plus 10ml methanol)  
♦ Dimethylsulfonoxid (DMSO) (Sigma) 
♦ Anti-CD31 paramagnetic Dynabeads 
(Dynal Biotech GmbH) 
♦ Anti-CD31 MicroBead Kit (Miltenyi 
Biotec GmbH) 
♦ Mouse anti-human S100 antibody 
(DAKO GmbH) 
♦ Rabbit anti-human von-Willebrand-
Factor (vWF) antibody (DAKO 
GmbH)  
♦ Secondary swine anti-rabbit FITC-
antibody, IgG (DAKO GmbH) 
♦ Mouse anti-human CD31 antibody 
(Dianova GmbH) 
♦ Mouse anti-human CD34 antibody 
(Dianova GmbH) 
♦ Mouse anti-human CD51/61 anti-
body (Dianova GmbH) 
♦ Mouse anti-human KDR antibody 
(Dianova GmbH) 
♦ Secondary goat anti-mouse FITC-
antibody, IgG (Dianova GmbH) 
♦ Anti-human CD105 FITC-conjugated 
antibody (ImmunoTools GmbH) 
♦ Isotype control IgG1 and IgG2 anti-
bodies (ImmunoTools GmbH) 
♦ CD31 APC-conjugated antibody 
(Miltenyi Biotec GmbH) 
♦ DiI acLDL cell tracker (Cell Systems) 
♦ Mowiol 4-88 (Calbiochem)
  
CULTURE MEDIA 
 
Attachment medium/Fibroblast medium 
♦ DMEM/Ham’s F12 
♦ 10% FCS 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin 
 
Table 2.  
Endothelial differentiation media 
EC-1 EC-2 EC-3 
 
♦ Endothelial Growth 
Medium-2 Microvascu-
lar (EGM-2MV) 
♦ 10 ng/ml VEGF 
♦ 10-6 mol/l rosiglitazone 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin 
 
 
♦ Endothelial Cell 
Growth   Medium 
(ECGM) 
♦ 50 ng/ml VEGF 
♦ 20 ng/ml IGF-1 
♦ 2% FCS 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin
 
 
♦ IMDM 
♦ 50 ng/ml VEGF 
♦ 100 ng/ml SCGF-β 
♦ 30% FCS 
♦ 1% BSA 
♦ 10-4 mol/l β-
mercaptoethanol 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin
 
 
HDMEC medium 
♦ EGM-2MV 
♦ 15% FCS 
♦ 100µg/ml Heparin 
♦ 7µg/ml IBMX 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin 
 
HUVEC medium 
♦ EGM-2 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin 
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Preadipocyte proliferation medium 
♦ DMEM/Ham’s F12 
♦ 10% FCS 
♦ 100 µl bFGF 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin 
 
Table 3.  
Adipogenic differentiation media 
Adipocyte differentiation medium 1 (d1-5) Adipocyte differentiation medium 2 (≥ d6) 
 
♦ DMEM/Ham’s F12 
♦ 100 nM dexamethasone 
♦ 10 µg/ml transferrin 
♦ 66 nM insulin 
♦ 1 nM triiodo-L-thyronine 
♦ 0.5 mM IBMX 
♦ 0.1 µg/ml pioglitazone 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin 
 
 
♦ DMEM/Ham’s F12 
♦ 100 nM dexamethasone 
♦ 10 µg/ml transferrin 
♦ 66 nM insulin 
♦ 1 nM triiodo-L-thyronine 
♦ 100 U/ml penicillin 
♦ 100 µg/ml streptomycin 
 
 
Table 4.  
Seading of SVF cells 
 Seeding  
density 
20.000/cm2 
(cell num-
bers) 
Seeding  
density 
30.000/cm2 
(cell num-
bers) 
Cells at  
confluency 
(cell num-
bers) 
Trypsin/ 
EDTA (ml) 
Growth me-
dium (ml) 
6-well 181.400 272.100 1.2 x 106 1 3 
T-25 0.5 x 106 0.75 x 106 2.8 x 106 2 5 
T-75 1.5 x 106 2.25 x 106 8.4 x 106 5 10-15 
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BUFFERS AND SOLUTIONS 
 
Collagenase buffer 
♦ 100 mM HEPES 
♦ 120 mM NaCl 
♦ 50 mM KCl 
♦ 1 mM CaCl2 
♦ 50 mM glucose 
♦ → pH 7.4 
 
Collagenase solution 
♦ 0.494 U/ml collagenase CLS Typ I 
♦ 1.5 % BSA 
♦ Collagenase buffer  
♦ → 1 ml collagenase buffer per 1 g  tissue 
 
Erythrocyte lysis buffer 
1. Stock solution: For 100 ml Aqua bidest:  
♦ 8.02 g NH4Cl 
♦ 0.84 g NaHCO3 or KHCO3 
♦ 0.37 g EDTA (Di-Na-salt) 
♦ 100 ml of this solution plus 900 ml Aqua bidest 
♦ → pH 7.4 
2. Working solution: 
♦ Stock soltution diluted 1:10 with Auqa bidest  
 
MACS buffer 
♦ 2 mM EDTA 
♦ 0.1% BSA 
♦ PBS2- 
♦ → degassed by ultrasound 
 
FACS buffer 
♦ 2 mM EDTA 
♦ 0.2% FCS 
♦ PBS2- 
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ISOLATION OF SVF CELLS 
SVF cells were isolated from freshly excised human subcutaneous abdominal or mammary 
fat tissue at the Department of Plastic Surgery and Hand Surgery - Burn Center from patients 
who underwent elective operations (e.g. abdominoplasty, breast reduction, liposuction). In 
regards to the amount of human preadipocytes gained from fat tissue, the harvesting method 
plays a central role. There are two different surgical isolation methods for fat tissue. Firstly 
harvesting of adipose material can be performed by simple excision of adipose tissue during 
elective operations such as abdominoplasty, breast reduction and others. The second 
method is liposuction in which numerous diminutive fat pieces are isolated. This displays the 
most atraumatic version for the patient (Figure 8). Cell yields from liposuction vary enor-
mously in the literature, according to the harvesting procedure, from 1.6 x105 to approxi-
mately 2 x106 cells per gram of lipoaspirated human fat405,434.  
 
 
 
 
Harvesting of excised fat tissue was arranged by isolating the single fat lobules which were 
prepared by careful removal of capillaries and connective tissue. After mincing into small 
pieces of 2-6 mm in diameter with scissors, adipose tissue was washed with 0.9% NaCl and 
digested. Harvesting of adipose tissue by liposuction was performed according to Sydney 
Coleman. With the Coleman method, manually applied negative pressure using a 10-cc-
syringe with a blunt tip cannula minces the fat lobules and sucks the small pieces into the 
syringe (Figure 8)80. To guarantee cell viability no additional solutions were added. Harvest-
ing sides were predominantly abdomen and breast. Isolation methods were adapted to the 
methods of Rodbell330 and Björntorp44,45 with minor modifications. All procedures were per-
formed under sterile conditions under the laminar flow hood. Adipose tissue was either used 
directly after harvesting or stored for up to 24 hours at 4°C in DMEM High Glucose. Adipose 
Figure 8. Different isolation 
methods for fat  tissue 
Process of adipose tissue harvest 
from tissue excision, e.g. abdomin-
oplasty (A.) or lipoasiprates (B.). 
 A. 
 B. 
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tissue from aspiration was digested by collagenase treatment after washing with 0.9% NaCl 
to remove possible blood contamination.  
Digestion of excized and liposuctioned fat tissue was performed with 0.2% collagenase CLS 
type I (0.494 U/ml) and 1.5% BSA dissolved in collagenase buffer for 60 minutes at 37°C 
under constant shaking. The gained suspension was filtered through a 250 µm filter mesh 
and centrifuged at 700g for 7 minutes at room temperature. SVF cells were separated from 
mature fat cells by discharging the fat layer on top, containing the lipid-filled adipocytes. SVF 
cells located in the cell pellet on the bottom of the tube were resuspended in different culture 
media dependent on their further use (Figure 9). For separation of CD31- and CD31+ cells, 
the SVF cell pellet was resuspended in EGM-2 MV culture medium in order to enhance EC 
numbers and maintain EC characteristics of CD31+ cells in the SVF. For plain flow cytometry 
analyses and endothelial differentiation assays of SVF cells, cells were seeded in 
DMEM/F12 (1:1) with 10% FCS. Seeding was performed on fibronectin-coated culture flasks 
at a density of 30,000 cells/cm2. Cells were washed twice with 0.9% NaCl after 24 and 48 
hours to remove contaminating blood cells. 
  
52
adipose SVF
in culture
fat tissue fat lobules
digestion
filtration
centrifugation
separation
resuspention
seeding
SVF pellet  
 
 
CD31 DYNABEAD SEPARATION OF SVF CELLS 
To split CD31- from CD31+ cells two widely accepted methods for cell separation were ap-
plied, cell splitting with Dynabeads and with Microbeads. For endothelial cell separation the 
most frequently used surface protein is CD31 as it is expressed on all endothelial cells but 
also on platelets. To minimize platelet contamination cells were washed thoroughly with NaCl 
after harvesting and again with PBS2- before trypsinizing for Dynabead/Microbead separa-
tion. Cells were grown to subconfluence for three to five days, trypsinized after washing, re-
Figure 9. SVF cell isolation from    
excised tissue 
Excised adipose tissue is minced with 
scissors into single fat lobules and digested 
with a collagenase solution. The resulting 
suspension is then filtered through a nylon 
mesh to remove undigested components, 
specially fibrous tissue and small vessels. 
Subsequent centrifugation deposits the 
stromal vascular fraction (SVF) as a pellet 
at the bottom of the tube from the floating 
lipid layer (mature adipocytes) on top. The 
supernatant is removed by pipetting and 
followed by resuspension of the cell pellet 
which allows seeding of the SVF cells in a 
culture dish.  
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suspended in 10 ml cold PBS2-/0.1% BSA with 2 mM EDTA (MACS buffer) and washed by 
pipetting the cell suspension carefully. Cells were centrifuged at 400g for 5 minutes, resus-
pended in 8 ml cold MACS buffer and passed trough a 70 µm nylon mesh into a 15 ml tube. 
The mesh ensured that only single cells passed through by excluding cell clusters thereby 
maximizing the purity and percentage of CD31+ cells. Afterwards cells were counted with a 
Neubauer chamber to calculate cell numbers. To ensure optimal binding of paramagnetic 
beads cell concentration should not exceed 108 cells/ml sample volume. Before use Dyna-
beads were prepared by washing with cold MACS buffer. Dynabeads were suspended in 8 
ml cold MACS buffer in a 15 ml tube and pipetted thoroughly. Next the tube was placed into 
the magnetic rack for two minutes until the solution became clear and all beads had moved 
to the magnet. The see-through supernatant was discharged, the tube removed from the 
rack and the beads were resuspended anew in 8 ml cold MACS buffer by pipetting. This 
washing step was performed three times and Dynabeads were resuspended in the original 
volume again. To separate CD31+ cells from CD31- cells by anti-CD31 paramagnetic beads, 
cells were incubated with 200 µl washed CD31 Dynabeads for endothelial cells (25 µl 
beads/ml cell suspension) at 4°C for 30 minutes under constant rotation, allowing for binding 
of endothelial cells to the beads. Afterwards the bead-cell suspension was pipetted a few 
times to release cell clusters which may have formed during the incubation period. The tube 
containing the Dynabead-labeled cells was placed in the magnetic rack (Dynal MPC-1) for 2 
minutes until all beads were attached to the magnet (Figure 10). The supernatant with CD31- 
cells was transferred to a fresh tube by pipetting, centrifuged at 400g for 5 minutes, washed 
once with MACS buffer, and cells were subsequently seeded on fresh culture flasks. For iso-
lating CD31+ cells, three washing steps as described before were performed with Dynabead-
labelled cells. After the falcon tube was removed from the magnetic rack, CD31+ SVF cells 
with Dynabeads attached to the surface were resuspended in fresh DMEM/F12.  
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For attachment to culture flasks both cell types were cultivated in DMEM/F12 supplemented 
with 10% FCS in fibronectin-coated flasks over night at a density of 80.000 cells/cm2. Seed-
ing at high density was performed in order to keep proliferation times as low as possible until 
complete confluence was achieved, necessary for further differentiation experiments towards 
the adipogenic and endothelial lineage. 
 
CD31 MICROBEAD SEPARATION OF SVF CELLS 
Cells were grown to subconfluence, trypsinized after washing twice with PBS2-, resuspended 
in 10 ml MACS buffer and passed trough a 70 µm nylon mesh to remove cell clusters. Cells 
were resuspended in 60 µl cold MACS buffer to a maximum concentration of 1x 107 cells/   
60 µl buffer. 20 µl FcR Blocking reagent was added to minimise unspecific binding of Micro-
Beads to FcR domains. The gained suspension was vortexed thoroughly and 20 µl of CD31 
MicroBeads were added. Cells were incubated for 15 minutes at 4 °C to allow binding of 
beads to the cell surface. During the incubation period MACS columns were prepared by 
placing two columns in the magnetic fields of each MiniMACS separator. The columns were 
rinsed with 1 ml MACS buffer three times. After the incubation time non-attaching beads 
were removed from the suspension cells by washing once with 5 ml medium and subsequent 
centrifugation at 400g for 5 minutes. The supernatant was discharged, cells were resus-
pended in 500 µl MACS buffer (up to 108 cells) and transferred onto prepared MACS col-
B.
C. 
A. Figure 10. Splitting of SVF cells with 
paramagnetic CD31 Dynabeads 
Dynabeads are uniform, superparamagnetic 
polystyrene beads with a diameter of about 
4.5 µm. The beads are coated with a mouse 
IgG1 monoclonal antibody specific for the 
CD31 cell surface antigen PECAM-1. Re-
quired material for Dynabead separation 
includes the Dynal magnet, CD31 Dyna-
beads and a conical tube (A.). Washed Dyna-
beads are mixed with the cell sample and the 
beads ligate to the CD31+ target cells (red) 
after incubation (B.). After binding the posi-
tive cells are separated from the negative cells 
by a magnet, whereas the CD31+ cells attach 
to the magnet and the CD31- cells remain in 
the cell suspension (C.).  
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umns. CD31- cells were collected after passing through the column without attachment in a 
15 ml tube and columns were washed three times with 1 ml MACS buffer, each time once 
the column reservoir is empty. The total effluent was collected and the gained CD31- cell 
suspension was centrifuged at 400g for 5 minutes, washed once with 10 ml medium and 
seeded onto fresh culture flasks. CD31+ SVF cells, which attached to the columns, were de-
tached by removing the columns from the magnetic filed first and placing the columns in two 
fresh 15 ml tubes. Cells were immediately flushed out by adding 1 ml of medium to the col-
umns and firmly applying the plunger supplied together with the columns (Figure 11). 
 
 
 
 
 
Cells were washed once with 10 ml medium and resuspended in fresh DMEM/F12 (1:1) after 
centrifugation. Both CD31+ and CD31- cells were cultivated in DMEM/F12 (1:1) supple-
mented with 10% FCS at a density of 80.000 cells/cm2 over night for adherence to culture 
dishes. Seeding was performed at high density to keep proliferation times until complete con-
fluence was achieved as low as possible, necessary for further differentiation experiments 
towards the adipogenic and endothelial lineage. 
 
B. 
C. D. 
A.
Figure 11. Splitting of SVF cells with para-
magnetic CD31 MicroBeads 
MACS MicroBeads are superparamagnetic 
particles composed of a biodegradable matrix 
and have a diameter of about 50 nm. For direct 
magnetic cell labelling the cell suspension is 
incubated with CD31 MicroBeads giving 
enough time for the beads to bind to the CD31+ 
cells (red) (B.). Subsequently the cell suspen-
sion is transferred onto a MACS MS Column 
placed in a MiniMACS Separator (A.). The 
separator is a strong permanent magnet and 
generates a high-gradient magnetic field on the 
column matrix. MicroBead-labelled cells are 
retained in the magnetic field whereas unla-
belled cells pass through (C.). They are collected 
in a conical tube as the CD31- cell fraction. 
After the column is removed from the magnet 
the retained CD31+ cells are eluted by pushing 
the plunger down and flushing out the posi-
tively selected cells (D.). 
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CULTURING OF SVF CELLS  
Culture media were changed for both CD31- and CD31+ to either endothelial or adipogenic 
differentiation medium 12 hours after Dynabead or MicroBead separation, respectively (see 
Figure 12).  
To evaluate differentiation plasticity towards endothelium, three types of differentiation media 
were tested (Table 2). The first culture medium (EC-1) used was an endothelial differentiat-
zion medium for angiogenic progenitor cells according to Wang et al.409 and contained Endo-
thelial Growth Medium-2 Microvascular (EGM-2MV) with 10 ng/ml VEGF and 10-6 mol/l 
rosiglitazone. The second medium (EC-2), an endothelial differentiation medium, was Endo-
thelial Cell Growth Medium (ECGM) supplemented with 50 ng/ml VEGF, 20 ng/ml IGF-1, and 
2% FCS, according to Miranville et al.260 with minor modifications. The third culture medium 
(EC-3) tested was a hematopoietic and endothelial progenitor cell medium for peripheral 
blood progenitor cells according to Gehling et al. 125, containing IMDM, 50 ng/ml VEGF, 100 
ng/ml SCGF-ß, 30% FCS, 1% BSA, and 10-4 mol/l ß-mercaptoethanol.  
To perform adipogenic differentiation, cells were cultured in DMEM/F12 (1:1) supplemented 
with bFGF (10 ng/ml) and 10% FCS (referred to as proliferation medium) to obtain cell con-
fluency again. Lipid droplet development was then promoted for 21 days by changing me-
dium to DMEM/F12 (1:1) without serum addition, supplemented with 66 nM insulin, 100 nM 
dexamethasone, 0.5 mM IBMX, 0.1 µg/ml pioglitazone, 1 nM triiodo-L-thyronine, and 10 
µg/ml human transferrin (adipocyte differentiation medium 1, Table 3). After 5 days of incuba-
tion, medium was used as before but without IBMX and pioglitazone for 16 more days (adi-
pocyte differentiation medium 2, Table 3). Culture media were changed every three days.  
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CELL SPLITTING 
Medium was removed from the culture flasks and cells were washed twice with PBS2- to 
eliminate residual medium. According to the size of the culture flask trypsin/EDTA was added 
and cells were incubated at 37°C for 2-3 minutes. Serum-containing medium was supple-
mented to the trypsin/EDTA containing the detached cells in order to stop the enzymatic 
process. Cells were centrifuged at 1350 rpm for 5 minutes, resuspended in 5 to 10 ml fresh 
culture medium and counted with a Neubauer cell counting chamber under the phasecon-
trast microscope. Cell numbers were calculated as follows: Counted cells / 4 x 104 = cell 
numbers / ml. Subsequently cells were seeded at the desired density and medium was 
changed the following day to remove non-vital cells. 
 
Figure 12. Experimental design of 
Dynabead/Microbead splitting of 
SVF cell culture and separate 
differentiation of subpopulations 
towards adipogenic and andothe-
lial lineage 
SVF cells were cultured in EC me-
dium to enhance EC numbers prior to 
cell separation. After splitting with 
paramagnetic beads CD31- and 
CD31+ SVF cells were both cultured 
in endothelial and adipogenic differ-
entiation medium. Endothelial differ-
entiation was measured via capillary 
structure formation on Matrigel 
ECM and flow cytometry analysis. 
Adipogenic conversion was deter-
mined by GPDH activity and Oil Red 
O staining. 
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FIBRONECTIN AND MATRIGELTM COATING 
Fibronectin (1 mg) was diluted to a concentration of 0.02 mg/ml by adding 50 ml aqua ad 
injectabile (fibronectin working solution). The bottom of the culture flask was covered with 
fibronectin working solution and air-dried under sterile conditions. 
MatrigelTM Basement Membrane Extracellular Matrix is made out of Engelbreth-Holm-Swarm 
(EHS) mouse tumor. Major components of Matrigel include laminin, collagen IV, heparan 
sulfate proteoglycanes, entactin and nidogen212. Further it contains TGF-β, FGF, tissue 
plasminogen activator254 and other growth factors which naturally exist in the EHS tumor. 
Matrigel is known to support and provide several factors necessary for the study of angio-
genesis283,284. For testing the angiogenic potential of SVF cells in vivo the thin gel method 
was used. Culture flasks are coated with Matrigel in a thickness of about 0.5 mm and cells 
are plated on top. Matrigel was diluted 1:2 with serum-free medium (EGM2-MV without sup-
plement mix), placed in aliquots and stored at -20°C. To handle Matrigel exclusively pre-
cooled material should be used as Matrigel gels at temperatures over 5-10°C. One day prior 
to use Matrigel was thawn on ice at 4°C overnight and pipettes and culture plates were 
placed in the freezer at -20°C for precooling. Next day a bucket was filled with ice and Ma-
trigel, pipettes and culture plates were placed on ice to keep them cold. All experiments with 
Matrigel coating were perfomed with 6-well plates. About 500 µl of Matrigel were added per 
well of a 6-well plate (50µl/cm2) and culture plate was placed for one hour at 37°C to allow 
Matrigel to harden. Afterwards cells were seeded at a density of 30,000/cm2 (see Table 4) in 
EC medium to examine EC differentiation and capillary formation capacity. 
 
HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELL (HDMEC) ISOLATION 
HDMECs were isolated from freshly excised human skin at the Department of Plastic Sur-
gery and Hand Surgery - Burn Center from patients who underwent elective operations (e.g. 
abdominoplasty, breast reduction, flap surgery). The unprocessed skin was placed on a ster-
ile Petri dish with the epidermal, smooth side facing upward, and was cut into small pieces of 
5 x 5 mm2 with a scalpel and digested overnight with dispase II at 4°C. Afterwards the skin-
dispase mixture was incubated under constant shaking at 37°C for 30 minutes. Dispase II 
enables the separation and removal of the epidermis from the dermis. With sterile tweezers 
skin pieces were transferred in a fresh tube with 20 ml cold PBS2- to stop the dispase diges-
tion. After transferring onto a petri dish the epidermis was separated from the dermis by care-
fully peeling back the epidermal layer using sterile tweezers. The dermis was minced with 
scissors into small pieces in a 50 ml tube. The dermal layer was then digested in prewarmed 
0.2% collagenase CLS type I with 1.5% BSA in collagenase buffer (sterile filtered) for 90 
minutes at 37°C under constant shaking. Cell suspension was filtered through a 250 µm 
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mesh to remove contaminating fibrous tissue and afterwards culture medium was added. 
After centrifugation at 400 g for 10 minutes the cell pellet was resuspended in HDMEC me-
dium and cells were seeded on fibronectine-coated culture dishes. Cells were washed twice 
after 24 hours with 0.9% NaCl to remove possible blood contamination and cultured to sub-
confluency. At subconfluency cells were washed twice with PBS2- and incubated with Tryp-
sin/EDTA for two to three minutes and stopped with medium containing 10% FCS. Detached 
cells were counted with a Neubauer counting chamber and separated with CD31-Dynabeads 
and CD31-Microbeads as described earlier. Afterwards the CD31 positive HDMECs were 
seeded on fibronectin-coated chamber slides and 6-well plates in HDMEC medium. They 
were used as positive control for endothelial differentiation assays on MatrigelTM Basement 
Membrane Extracellular Matrix as well as flow cytometry analysis. 
 
HUMAN DERMAL FIBROBLAST ISOLATION 
Fibroblasts were isolated following the same procedure as with HDMECs from human skin. 
After separation with CD31 Dynabeads/Microbeads, the CD31 negative fibroblasts were 
seeded on chamber slides, 6-well plates, and T75 culture flasks in fibroblast medium as 
negative control. 
 
HUMAN UMBILICAL VEIN ENDOTHELIAL CELL ISOLATION 
HUVECs were isolated from human umbilical veins that had been received as a gift from the 
Department of Pathology. The injured ends of each vein were removed and a feeding needle 
was carefully inserted into the vein and fixed with a clamp. Afterwards the vein was rinsed 
with 20 ml HEPES/6 mM EDTA via a syringe to remove possible blood contamination. An-
other feeding needle was inserted at the other end of the vein, fixed and the flow through 
was checked with another 20 ml of HEPES/6 mM EDTA. A second syringe was filled with 5 
ml trypsin/EDTA (37 °C warm) to replace the first one. Trypsin/EDTA was injected into the 
umbilical vein and the cord was inserted in U-shape into a 500 ml vial filled with 37°C pre-
warmed PBS2-. After incubation for 20 minutes at 37°C in the water bath, the cord was 
placed on a sterile operation cloth and massaged for five minutes to release HUVECs from 
the vessel wall. 8 ml HEPES/6 mM EDTA was filled into another syringe and the syringe was 
connected to the feeding needle. The cord vein was flushed thoroughly and the eluted fluid 
was collected in a 50 ml tube containing 2 ml FCS to stop the digestion. After centrifugation 
at 400g for 5 minutes at room temperature cells were resuspended in HUVEC medium and 
subsequently seeded on fibronectin-coated T75 culture flasks. They were used as positive 
control for endothelial differentiation assays on MatrigelTM Extracellular Matrix as well as flow 
cytometry analysis. 
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FLOW CYTOMETRY ANALYSIS 
To perform flow cytometry analyses, freshly isolated cells were incubated for 15 minutes with 
erythrocyte lysis buffer at 4°C. For staining with DiI, cells were washed with PBS2-, and incu-
bated with DiI-ac-LDL (acLDL) (10 µg/ml) for one hour at 37°C. Afterwards cells were 
washed twice with plain medium, once with PBS2-, and fixed with 4% paraformaldehyde 
(PFA). Next, cells were centrifuged at 400g for 10 minutes and resuspended in PBS2- con-
taining 0.2% FCS and 2 mM EDTA. For incubation with primary anti-human CD31, CD34, 
KDR, CD51/61, vWF, S100, and CD105-FITC, cells were also fixed with 4% PFA, resus-
pended in PBS containing 0.2% FCS and 2 mM EDTA, and kept at 4°C for 30 minutes. 
Washing and incubation with secondary FITC-conjugated antibodies was performed for 30 
minutes at 4°C with all samples except for the already FITC-labelled CD105. For additional 
staining with CD31 APC-conjugated antibodies to generate double-labelling, cells were incu-
bated with CD31-APC for 10 minutes at 4 °C, washed and resuspended in PBS containing 
0.2% FCS and 2 mM EDTA. Labelled cells were analyzed by flow cytometry using a FACS 
Calibur apparatus (Beckton Dickinson) and CellQuest Pro analysis (Figure 14). 
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Figure 13. Flow cytometry 
analysis 
Flow cytometry analysis allows 
simultaneous measuring of relative 
cell size (FSC), cell granularity and 
internal complexity (SSC) and 
fluorescence intensity (A.). The 
major components comprise a fluid 
system, an optical system with 
laser, reflector and filter device. 
According to the fluorescence 
staining applied wavelengths differ 
between 450 nm and 700 nm. FITC 
requires a laser wavelength of about 
488 nm in the green range, con-
trariwise APC has its optimum at 
633 nm in the red spectrum (B.).  
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Isotype controls for IgG1 and IgG2a were used as recommended by the supplier to exclude 
non-specific binding of antibodies and were always negative. Each labelling with FITC-CD 
markers was compared to control cells exclusively stained with the secondary FITC-
conjugated fluorescence antibody. The percentage of positively stained cells was determined 
after correction for the percentage of cells reacting with the secondary FITC antibody. Stain-
ing of CD31+ as well as CD31- SVF cells was performed on the day of adipogenic and endo-
thelial differentiation induction. 
 
IMMUNOSTAINING WITH VON-WILLEBRAND-FACTOR 
For immunostaining with vWF cells were seeded on glass slides in chamber slides culture 
dishes. Preceeding the staining procedure culture medium was removed from chamber 
slides containing adherent cells and glass slides were washed twice with PBS2-. Cells were 
fixed in cold acetone for 20 minutes at 4°C, acetone was removed again and glass slides 
were dried at room temperature for a few minutes until completely parched. Glass slides 
were placed into PBS2- and positioned into coverplates. Coverplates were rinsed once with 
fresh PBS2- and each incubated with 100 µl primary anti-vWF antibodies for one hour at room 
temperature. Antibodies against vWF were diluted 1:200 with PBS2-/1% BSA prior to use. 
After washing three times with PBS2-, slides were stained with 100 µl FITC-conjugated sec-
ondary antibodies each for one hour at 37°C. FITC antibodies were diluted 1:30 with PBS/1% 
BSA before use as well. After washing three times with PBS2-, staining of the cell nucleus 
was performed by applying 100 µl DAPI solution for each coverplate and incubating for 15 
minutes at room temperature. After washing three times with PBS2- glass slides were re-
moved from coverplates, coated with two drops of Mowiol 4-88 and covered with small glass 
slides. Mowiol was hardened for a few hours at 4°C in the dark. Detection of vWF expression 
was performed by fluorescence microscopy. vWF staining of CD31+ and CD31- SVF cells 
was performed on the same day as adipogenic and endothelial differentiation induction to 
ensure purity of cells used for differentiation assays. 
 
DETERMINATION OF GLYCEROL-3-PHOSPHATE DEHYDROGENASE (GPDH) ACTIV-
ITY  
To evaluate preadipocyte differentiation on a molecular level, the activity of GPDH was 
measured with a kit system from Takara. GPDH is a representative molecular key marker of 
adipogenic conversion335, which has been used for decades to measure preadipocyte differ-
entiation298,368.  
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To perform GPDH assays, culture medium was removed and cells were washed twice with 
PBS2-. Cell lysis was induced by adding 1 ml “Enzyme Extraction Buffer” per T25 culture 
flask. Culture flasks were incubated for three to five minutes at 37°C until cell lysis was com-
pleted. Afterwards the lysate was transferred to a 15 ml tube and diluted to two-fold by add-
ing 1 ml “Dilution Buffer”. To gain the desired four-fold dilution, 250 µl of the cell suspension 
were added to another 250 µl “Dilution Buffer” in a fresh 1.5 ml Eppendorf cup. The samples 
are stable for one hour on ice if necessary. 25 µl of each four-fold diluted sample was trans-
ferred into each 96-well. GPDH activity was determined by measuring absorbance at 340 nm 
with an ELISA reader. The 96-well plate was inserted into the reader and 100 µl “Substrate 
Solution” was pipetted to each sample via multi-channel pipette. As the reaction starts imme-
diately after mixing the cell suspension with “Substrate Solution”, it was substantial to add the 
“Substrate Solution” quickly to each 96-well. This was achieved by the application of a multi-
channel pipette. Next, the ELISA reader was started at once to measure the GPDH activity. 
The enzyme activity was measured ten times during the redox reaction. GPDH activity was 
calculated with the following formula supplied by Takara:  
GPDH activity (units / ml) = ΔOD340 x 2.06 x dilution ratio of the sample 
 
coenzyme for the reversible conversion between both substrates and can be measured by the GPDH assay through the secondary 
decrease of NADH.  GPDH activity is calculated by measuring the reduction of NADH via declining absorbence at 340nm. 
Dihydroxyacetone phosphate + NADH + H+ → Glycerol-3-phosphate + NAD+ 
 
Figure 14. Enzymatic reactions in glycerol-3-
phosphate dehydrogenase (GPDH) assay 
Sequential binding of the fatty acids activated as 
acyl-CoAs to glycerol-3-phosphate is a major step in 
lipid biosythesis. In the liver glycerol-3-phosphate is 
directly synthesised from glycerol with the help of 
the glycerol kinase. Due to the absence of the glycerol 
kinase in adipose tissue und muscle, glycerol-3-
phosphate is produced by the reduction of dihy-
droxyacetone phosphate in combination with 
NADH. As dihydroxyacetone phosphate is an inter-
mediate product in the glycolytic pathway, lipid 
synthesis in adipose tissue and muscle cannot pro-
ceed without glucose. The enzyme which catalyses 
the conversion between dihydroxyacetone phosphate 
and glycerol-3-phosphate is the glycerol-3-phosphate 
dehydrogenase (GPDH). GPDH requires NAD as a 
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OIL RED O STAINING 
Oil Red O staining is an established staining method for intracellular lipid vacuoles. This 
method stains lipid droplets with a red colour so that even small droplets can be identified in 
the cytoplasma and the percentage of lipid-containing cells can be validated. Besides lipid 
droplets intracellular stress vacuoles are stained slightly red as well when incubated with Oil 
Red O. The staining intensity of stress vacuoles is minor to that of lipids and these vacuoles 
are extremely small in diameter so that they can be distinguished from lipid droplets in light 
microscopy examination. 
Oil Red O dye (0.5 g) was diluted in 100 ml of 99% isopropanol. This stock solution was 
mixed 6:4 with aqua bidest and stored for 24h at room temperature. Afterwards the solution 
was filtered to remove small dye particles. Monolayer cultures were washed twice with PBS2- 
and fixed with 10% cold PFA and incubated for five hours at 4°C. After removing the PFA Oil 
Red O working solution was added to culture flasks and samples were kept at room tempera-
ture for at least two hours. After washing twice with PBS2- the stained cells were kept in 10% 
PFA and examined by light microscopy to count lipid-filled adipocytes. 
 
CELL COUNTING 
To dertermine (i) the percentage of differentiated to undifferentiated cells, (ii) to detect those 
cells attached to Dynabeads as well as (iii) cells stained for vWF under the fluorescence mi-
croscopy, cell counting was performed under the phasecontrast or fluorescence microscope 
with 100x magnification.  
Cells were counted in six randomly chosen fields (six fields per culture flask). Differentiated 
and undifferentiated cells were counted to determine the percentage of both cell types and 
compare the differentiation level between different wells. The same was done with cells car-
rying Dynabeads on their surface and vWF positive cells appearing green under fluores-
cence light.  
 
STATISTICAL EVALUATION 
Data of expression of surface markers and GPDH activity were expressed as mean value ± 
standard deviation. The significance of differences between CD31+ and CD31- cell differen-
tiation was evaluated using the t-test. Differences with p<0.05 were considered significant 
and p<0.01 highly significant. 
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RESULTS 
 
COMPARISON OF EXCISED FAT TISSUE VERSUS LIPOSUCTION MATERIAL 
The surface expression of freshly isolated SVF cells from liposuction and excision was char-
acterized by flow cytometry without performing any previous purification. SVF cells harvested 
from excised fat tissue show strong labelling for CD34 and a less intensive staining for KDR 
(Figure 15 A., Table 5). These cells also comprise a small population of 5-10% of CD31 and 
CD51/61 positive cells. SVF cells derived from liposuction aspirate (Figure 15 B.) are positive 
for CD34, similar to cells from excised tissue (compare Table 5). CD31 and CD51/61 fluores-
cent labeling was stronger in liposuctioned SVF cells with up to 40% CD31 positive cells 
(p=0.05 compared to CD31 expression in excised tissue). KDR was much more positive in 
lipoaspirate than in excised fat (p<0.01).  
Following standard culture conditions for two weeks in DMEM/F12 containing 10% FCS, cells 
from lipoaspirate remained positive for CD34 in the same percentage as freshly isolated cells 
while CD34 expression in excised fat decreased. Endothelial cell marker CD31 decreased in 
liposuction and excised material by about 50%, CD51/61 shows a similar tendency (Table 5). 
During cell cultivation, KDR expression or selection, respectively, increased in excised tissue 
cells but decreased in liposuction material.  
Fibroblasts, HDMECs and HUVECs were used as controls. Fibroblasts were negative for 
CD31, vWF, CD51/61, KDR, S100, acLDL, positive for CD105, and slightly positive for 
CD34. HDMECs showed positive results for CD31, vWF, acLDL, CD34, and KDR, as well as 
slightly positive staining for CD51/61. HUVECs were positive for CD31, acLDL, CD34, KDR, 
and negative for CD51/61 (Figure 21). Isotype controls for IgG1 and IgG2a were always 
negative (Figure 15).  
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Figure 15. Characterisation of SVF cells from excised versus liposuctioned adipose tissue 
SVF cells were isolated from excised (A.) and liposuctioned (B.) adipose tissue by collagenase digestion and immedi-
ately analyzed by flow cytometry without any previous purification or culturing. Cells were screened for the expres-
sion of CD31, CD34, CD51/61, and KDR. IgG1 and IgG2a were used as isotype controls. Also, staining with secon-
dary FITC-conjugated fluorescence antibodies (FITC control) only was monitored.  
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Table 5. Expression of surface markers on adipose tissue derived SVF cells 
SVF cells were isolated from excised adipose tissue or liposcution material, respectively, as described in Figure 15, and cul-
tured in DMEM/F12 plus 10% FCS for 14 days, followed by flow cytometry analysis. Given is the expression of the surface 
markers CD31, CD34, CD51/61, and KDR in percentage. Fibroblasts were used as negative, HDMECs and HUVECs as 
positive control. Data are derived from three individual experiments. 
 
 
excision 
day 0 
excision 
day 14 
liposuction 
day 0 
liposuction 
day 14 
CD31+ 10% ± 2% 6% ± 3% 24% ± 15% 12% ± 5% 
CD34+ 57% ± 3% 36% ± 10% 57% ± 20% 57% ± 4% 
CD51/61+ 4% ± 1% 5% ± 2% 11% ± 8% 7% ± 3% 
KDR+ 14% ± 5 52% ± 8 43% ± 23% 23% ± 7% 
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CHARACTERISATION OF SURFACE MARKERS AND MORPHOLOGICAL CHANGES IN 
SVF CELLS IN CULTURE 
The developement and changes in surface marker expression under standard culture condi-
tions were measured after one and two weeks (Figure 16). Preadipocytes loose their differ-
entiation capacity when cultured in standard medium for several passages. Here we focused 
additionally on stem cell markers (CD34, KDR and S100) to evaluate the differentiation po-
tential after long term culture (compare also Table 5). 
Unpurified SVF cells from liposuctioned and excised fat tissue were cultured in DMEM/F12 
plus 10% FCS for either one or two weeks and flow cytometry was performed. After one 
week CD34, KDR and S100 were still fully expressed by SVF cells (Figure 16 A.), after two 
weeks all three stem cells markers decreased (Figure 16 B., Table 5). 
 
A.
B.
CD34 KDR
CD34 KDR
S100
S100
 
 
Figure 16. Flow cytometry analysis of preadipocytes during culture 
SVF cells without prior purification were cultured in DMEM/HAM´s F12 with 10% FCS. Changes in surface 
protein expression during proliferation were measured by flow cytometry for CD34, KDR and S100 on day 7 (A.) 
and day 14 (B.). 
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IN VITRO DIFFERENTIATION OF UNPURIFIED SVF CELLS UNDER ENDOTHELIAL ME-
DIUM CONDITIONS 
Freshly isolated preadipocytes responded significantly different to the cultivation in the vari-
ous EC media (Figure 17). SVF cells were tested for their EC development on plain plastic 
culture dishes and were stained with vWF and DAPI. In medium 1 (EC-1) only minor prolif-
eration and no formation of capillary structures was detected in vWF positive cells (Figure 17 
A.-D.). Medium 2 (EC-2), in contrast, induced substantial proliferation and enhanced tubular 
network formation of vWF positive cells (Figure 17 E.-H.). Further positive stained cells 
showed capillary structures with widespread network connections (Figure 17 F.). Medium 3 
(EC-3) also allowed significant cell proliferation but no network formation (Figure 17 I.-M.). 
Standard proliferation medium for preadipocytes showed equal results in proliferation and 
tubular structure formation as medium EC-1 (data not shown). 
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Figure 17. Preadipocytes in different EC media without prior purification 
Adipose progenitor cells were screened for EC development on plastic culture dishes by immunofluorescence staining with 
vWF and DAPI. All pictures are vWF images except for D., H., M. (vWF-DAPI merged), A.-D. Medium 1, E.-H. Medium 
2, I.-M. Medium 3. Magnification in A., E., I. is x20, in B., F., K. is x50, in C., G., L., D., H. and M. is x100. 
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SPLITTING AND PURITY ANALYSIS OF CD31- AND CD31+ SVF CELLS 
To further characterize the unpurified SVF population, von-Willebrand factor immunofluores-
cence staining was performed 12h after cell isolation and culture in DMEM/F12, 10% FCS. 
Freshly harvested SVF cells from excised fat tissue contain a small amount of approximately 
10% of vWF positive (Figure 18 A.) and CD31 positive cells, as revealed by microscopical 
counting and flow cytometry analyses (compare Table 5). Cultured under endothelial differ-
entiation conditions (EC-2) in the presence of VEGF and IGF-1, these SVF cells develop 
tubular structures on plastic without Matrigel™. This was demonstrated by vWF-
immunofluorescence staining after culturing for two weeks (Figure 18 B.). Following separa-
tion into CD31- and CD31+ cells by Dynabeads or MicroBeads, respectively, CD31- SVF cells 
show no expression of vWF or CD31 (Figure 18 C., E.), neither after one nor after two weeks 
culturing in proliferation medium. Furthermore, CD31- cells do not reveal endothelial network 
formation on plastic culture dishes (Figure 18 C.). Analyzing expression of S100, an early 
marker of adipogenesis, these cells are found almost 100% positive in flow cytometry (Figure 
18 D.-E.). CD31+ cells, in contrast, demonstrate strong vWF expression (97% ± 2% stained 
cells) and CD105 staining after one week. The Dynabead isolation procedure demonstrates 
to be effective since 95% ± 5% of the cells carry Dynabeads, confirming that they are posi-
tive for CD31 (Figure 18 F.-I., Figure 18 E.). Cells isolated with CD31 MicroBeads show 
strong staining for CD31 in flow cytometry (Figure 18 L., N., P.). Furthermore CD31+ Mi-
croBead-isolated cells reveal the same surface expression characteristics for CD105 and 
vWF as after isolation with Dynabeads. During proliferation, magnetic beads initially remain 
bound to the cells and resist washing steps, however, cell proliferation reduces bead num-
bers continuously.  
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Figure 18. Scheme of the application of CD31 Dynabead separation for SVF cells 
Freshly isolated SVF cells from excised tissue were analyzed by fluorescence microscopy after isolation and transferred to 
tissue culture dishes (A.). Cells were then either cultured in EC medium (EC-2) without Dynabead treatment and analyzed 
again after two weeks (B.) or separated by CD31 Dynabeads or MicroBeads into a CD31- (C.-E.) and a CD31+ fraction (F.-
P.). To confirm the purity of the isolation procedure, flow cytometry was performed with CD31- cells double-stained for 
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CD31 and S100 expression (D. and E.) and with CD31+ cells double-labelled for CD31 in combination with CD105, vWF, 
or CD34 (K.-P.). For fluorescence microscopy, cells were stained with vWF and DAPI. All pictures except for F. (vWF alone) 
and I. (bright field and vWF, merged) are vWF-DAPI merged images. F.-I., K., M. and O.: Dynabead cell sorting, L., N. and 
P.: MicroBead cell sorting. Arrows in H. and I. indicate Dynabeads attached to cell surfaces. Magnification in A., B., C., F., 
G. and I. is x200, in H. x400. 
 
 
DIFFERENTIATION POTENTIAL OF CD31- AND CD31+ SVF CELLS TOWARDS EC 
LINEAGE 
To evaluate endothelial differentiation potential of CD31- SVF cells morphologically, this cell 
fraction was seeded onto Growth Factor Reduced Matrigel™ in EC-2 or EC-3 culture medium, 
respectively, and tube formation was assayed. Cells form three-dimensional tube-like struc-
tures in both media (Figure 19 A.-D.), while EC-2 medium also allows formation of extensive 
intercellular tube networks (Figure 19 C.-D.). CD31+ SVF cells showed equal results com-
pared to CD31- SVF cells when seeded on Matrigel™ ECM (data not shown). HUVECs, which 
were used as a positive control, also formed networks but were not able to grow three-
dimensionally (Figure 19 E.-F., compare to Figure 19 C.). 
Next, endothelial differentiation of CD31- cells grown in EC-2 or EC-3, respectively, was ana-
lyzed by flow cytometry to determine the quantitative expression of the surface markers 
CD34, KDR, and acLDL (compare Table 6). In EC-3 medium CD31- SVF cells express CD34 
by up to 46% and KDR up to 90%, demonstrating the capacity of this medium to enhance 
stem cell characteristics of SVF cells (Figure 20 A.). In EC-2 medium CD34 and KDR ex-
pression is significantly lower (p=0.003 for CD34, p=0.006 for KDR) (Table 6, Figure 20 B.). 
In both media, cells were positively stained for acLDL confirming differentiation towards an 
endothelial phenotype (Figure 20).  
HDMECs and HUVECs were used as positive (Figure 21), fibroblasts as negative control. 
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Figure 19. Morphological analysis of endothelial differentiation of CD31- SVF cells and HUVECs 
CD31- cells were isolated from the SVF by Dynabeads. Endothelial differentiation was performed in a stem cell medium (EC-
3, A.-B.) and an endothelial differentiation medium (EC-2, C.-D.) on Matrigel™. As control human umbilical vein endothe-
lial cells (HUVECs) were cultured in EGM-2 medium on Matrigel™ (E.-F.). Endothelial differentiation was analyzed by 
light microscopy. Shown are bright field micrographs at a magnification of x100. ►, capillary tubules; ?, three-dimensional 
networks.  
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Figure 20. Flow cytometry  analysis of CD31- cells differentiation under optimized medium conditions 
CD31- cells were isolated from the SVF and endothelial differentiation was induced by applying a stem cell medium (EC-3, 
A.) or an endothelial differentiation medium (EC-2, B.), respectively. Quantitative expression of the surface markers CD34, 
KDR, and acLDL was determined in flow cytometry. 
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 culture medium EC-2 culture medium EC-3 
CD34+ 2% ± 1% 37% ± 9% 
KDR+ 19% ± 15% 78% ± 12% 
acLDL 70% ± 5% 77% ± 7% 
 
Table 6. Expression of surface markers on CD31- SVF cells under endothelial medium conditions  
To evaluate differentiation of CD31- cells towards endothelium, CD31- cells were isolated from the SVF by Dynabeads and 
grown in EC-2 or EC-3, respectively, followed by quantitative analysis of the expression of the surface markers CD34, KDR, 
and acLDL (compare  Figure 20). Data are from three individual experiments. 
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Figure 21. Flow cytometry analysis of HUVECs 
HUVECs were used as control in flow cytometry analysis for the presence of endothelial cell markers as CD31, CD51/61, 
CD34, KDR and acLDL uptake. 
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IN VITRO DIFFERENTIATION OF SVF CELLS UNDER ADIPOGENIC MEDIUM CONDI-
TIONS 
Unseparated SVF cells from excised tissue differentiate under adipogenic culture conditions 
to almost 90% into adipocytes showing large lipid vacuoles after 21 days in adipogenic me-
dium (data published elsewhere). Regarding the separated SVF cell fractions, the CD31- 
cells could differentiate into mature adipocytes by nearly 100%, as demonstrated by light 
microscopy and Oil Red O staining in Figure 22 A.-D.. Interestingly, purified CD31+ mature 
endothelial cells from the SVF also convert into adipocytes after 21 days under adipogenic 
culture conditions. Undergoing differentiation, cells are viable and healthy with no signs of 
apoptosis present. From microscopical cell counting, approximately 65% of CD31+ cells pre-
sented accumulation of lipid vacuoles equivalent to an adipocyte phenotype. As can be seen 
from Figure 22 E.-G., CD31+ cells have CD31 Dynabeads attached to their cell membranes 
which confirms their CD31 surface expression. When comparing GDPH activity of both CD31 
subsets, CD31+ cells showed a GPDH activity of 64% ± 11% compared to GPDH levels of 
CD31- cells set 100% (Figure 23). Lipid droplets appeared approximately 2-3 days later dur-
ing differentiation in CD31+ than in CD31- cells. Applying flow cytometry, the proliferating 
CD31+ cell fraction was screened for the presence of the surface marker CD34 before induc-
ing adipogenic differentiation. As shown in Figure 18 O.-P., approximately 45% of the cells 
express CD34.  
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Figure 22. Morphological analysis of in vitro differentiation of SVF cells under adipogenic medium conditions 
SVF cells were separated into CD31- (A.-D.) and CD31+ (E.-H.) by Dynabead treatment. Both fractions were independently 
differentiated towards mature adipocytes. All pictures, except for D. and H. which shown oil red staining results, are bright 
field images. Shown in the left upper corner of G. is a high-power magnification of a differentiating cell with Dynabeads 
attached. Arrows in E., F., and G. indicate Dynabeads attached to cell surfaces. Magnification in A.-D., E. and H. is x100, in 
F. and G. is x200. 
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Figure 23. Quantitative analysis of in vitro 
differentiation of SVF cells in adipogenic 
medium  
SVF cells were separated into CD31- and 
CD31+ cells by Dynabeads, independently 
cultured in proliferation medium, and differen-
tiated at confluence. Differentiation of the 
CD31+ fraction as determined by GPDH activ-
ity was measured after 3 weeks relative to 
CD31- cells. Results are from three individual 
experiments. *, p=0.01 compared to standard 
differentiation of CD31- cells. 
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DISCUSSION 
 
The stromal vascular fraction (SVF) of adipose tissue is a heterogenous cell population and 
therefore very hard to characterize. Although there are similar findings about the surface pro-
tein expression of SVF cells, much controversy remains. The cell fractions that have been 
used for surface analyses and differentiation assays cannot be compared since some re-
search groups apply liposuction aspirates60,252 133 or excised fat tissue260,314; others use more 
purified, cell-sorted fractions260,350, while still others have identified cell surface structures 
from cells not before culturing for several passages60. This leads to cell fractions with differ-
ent surface characteristics and different proliferation and differentiation behaviours. In this 
thesis SVF cells from lipoaspirate and excised fat were screened for the presence of CD34, 
KDR, CD31 and CD51/61. The rational for this was threefold: to (i) illustrate the differences 
between SVF cells isolated from excised versus liposuction material, (ii) to determine the 
relative amount of endothelial and hematopoietic progenitor cells in the freshly isolated SVF, 
and (iii) to be aware of potential cellular contaminations, especially endothelial cells, which 
might cause a false-positive differentiation result. Additionally, cells were cultured for two 
weeks in standard medium to promote proliferation and to evalutate possible changes of sur-
face protein expression under long-term culture conditions.  
After isolation of SVF cells the cell pellet is naturally contaminated with endothelial cells. 
When measuring the differentiation potential of SVF cells into endothelial cells, already in-
corporated ECs might mimic a successful transdifferentiation of SVF cells. Therefore, it is not 
possible to evaluate whether endothelial cells were transdifferentiated from SVF cells or if 
they were already present in the applied SVF cell fraction before starting the experiment. To 
determine the growth potential of contaminating ECs after isolation of SVF cells, different EC 
growth media and a standard proliferation medium for preadipocytes were tested.  
To analyze the differentiation plasticity of SVF cells towards endothelial structures and adi-
pose tissue, exclusively purified cell fractions were used to exclude cell contamination and 
allow a solid analysis. Therefore, the cell pellet was splitted into a CD31+ and a CD31- cell 
fraction using paramagnetic beads. After confirming purity of both cell fractions, CD31+ and 
CD31- SVF cells were cultured in EC media or adipogenic differentiation medium. For endo-
thelial differentiation only EC-2 and EC-3 medium were applied as these two media showed 
best potential for EC proliferation and differentiation according to Study 3.  
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TISSUE ENGINEERING WITH ADIPOSE DERIVED ADULT STEM CELLS 
Soft tissue defects remain a challenge and often difficult problem in plastic and reconstruc-
tive surgery. There is high clinical need for adequate reconstruction of extended soft tissue 
defects as found after deep burns, trauma, or tumor resections.  
The application of autologous fat tissue to repair soft tissue defects seems most reasonable 
in its approach as excess amounts of adipose tissue are found all over the human body. Adi-
pose tissue can be easily obtained through liposuction or elective operations and has been 
used for transplantation or in soft tissue tissue engineering projects. Although there is re-
markable progress in this research field, serious problems remain. Transplantation of autolo-
gous adipose tissue to a defect site often results in 40-60% of graft volume loss over time. 
One reason for significant tissue resorption is that large fat grafts never acquire sufficient 
vascularization. Inadequate tissue vascularization restrains the supply of oxygen and nutri-
ents to the graft followed by consecutive tissue destruction406 and long-term tissue resorpti-
on304,303. Therefore the use of mature fat tissue for transplantation has not been consistently 
successful in patients58,95,108,201,304,305,362.  
More promising in the context of soft tissue reconstruction is the use of adipose tissue de-
rived progenitor cells seeded on biomaterials. By harvesting viable cells from patients healthy 
autologous preadipocytes can be expanded through cell culture replication. Cells may then 
be seeded onto scaffolds which need to support cell growth, proliferation and differentiation 
of the progenitor cell fraction into mature fat cells. The scaffold construct is normally ab-
sorbed over time due to its biodegradable material and ideally, exclusively mature, well-
vascularized healthy adipose tissue remains.  
Preadipocytes are deemed more advantageous as cell source for adipose tissue engineering 
than mature adipocytes because they can be easily obtained, cultured, and expanded. Due 
to the ability to generate large cell numbers and finally differentiate into various cell types 
other than adipocytes97,157,162,433,434, preadipocytes are thought to have high potential in the 
future development of soft tissue engineering.  
 
PRESENT PROBLEMS AND HURDLES 
Though several strategies using polymeric materials seeded with preadipocytes have been 
successful to induce adipose tissue formation in vivo, one often quoted shortcoming with 
these strategies is delayed growth in volume of the tissue constructs. This has been attrib-
uted mainly to slow vascularisation of the tissue leading to tissue resorption, oil cysts and 
fibrosis253,307,363. Oxygen and nutrients supply are the limiting factors for the survival of trans-
planted cells. Especially adipose tissue engineering fails due to inadequate blood supply as 
mature fat cells face cell death if they do not get in contact with surrounding capillaries by 
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inosculation within the first four days363,408. In conclusion, sufficient vascularisation and ap-
propriate cellular differentiation are two key problems in soft tissue engineering. 
A further problem in organ and tissue transplants which will come into place once cell differ-
entiation and vascularisation have been addressed is the immunological rejection of the do-
nated tissue by the patient in non-autologous methods or cell culture using FCS. Strategies 
in tissue engineering ascertain possible solutions to these problems225, including the applica-
tion of preadipocytes instead of adipocytes due to better proliferation capacity34,304 and hy-
poxia tolerance in precursor cells406, the exertion of autologous serum during in vitro cell cul-
ture160,161 and improvement of applied biomaterials159 among others.  
 
HOW TO MANAGE INSUFFICIENT VASCULARISATION 
Current methods to induce neovascularisation, the formation of a new vascular network, 
within a tissue-engineered construct reveal limitations. Methods for adipose tissue angio-
genesis include co-culture of adipose cells with ECs in tubular scaffolds to induce vessel 
formation. Although growth factors help in the formation of capillary structures, the generated 
vessels are not long lasting304,303. The creation of vasculature prior to implantation allows the 
tissue to receive nutrients faster because it does not have to form its vasculature. However, 
the tissue may still not receive the required nutrition47. Other vascularisation methods com-
prise ingrowing of host vessels into the tissue construct leading to revascularisation of the 
implanted material, but again insufficient nutrient supply remains a problem for the center of 
the scaffold304. The relationship between ADAS cells and ECs as well as the role of certain 
growth factors are not sufficiently understood to proceed towards a viable graft of relevant 
size. Additionally, the potential of ADAS cells to differentiate into adipocytes and ECs upon 
availability of the proper stimuli could be the key for confecting a vascularised fat graft with 
sustained and increased volume. Therefore, this thesis studied the differentiation potential of 
cells to convert from adipose tissue to endothelium and vice versa via progenitor cells. 
 
CHARACTERIZATION OF THE SVF 
Taking the broad mixture and combinations of cell surface CD markers, it is logical that the 
SVF is not a unique population, but rather a pool of various progenitor cells including mature 
ECs, too.  
ADAS cells exhibit differentiation plasticity similar to that of bone marrow stem cells, as men-
tioned in the introduction. The cells are multipotent adult stem cells and have the ability for 
multilineage differentiation429,433,434. Further similarities between ADAS cells and BMSCs 
have been described in the literature focussing on growth kinetics and expansion capacity, 
cell senescence, and protein surface expression (compare Table 1). 
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As shown by flow cytometry, freshly isolated SVF cells from excised as well as liposuctioned 
adipose tissue comprise a significant population of progenitor cells as shown by strong ex-
pression of CD34 and KDR (Figure 15). However, the SVF also contains a population of 
CD31, CD51/61, and vWF positive cells, demonstrating a contamination with mature ECs. 
CD31 and CD51/61 expression was stronger in liposuction SVF cells, with up to 40% CD31 
positive cells, emphazising the higher amount of contaminating ECs in lipoaspirates than in 
excised fat (5-10% ECs, Table 5). The vWF expression of 10% for excised tissue as deter-
mined by microscopical cell counting (Figure 18 A.) completely matches the findings on 
CD31 and CD51/61 expression in flow cytometry (compare Table 5). 
After cell culture in DMEM/F12 with 10% FCS for two weeks, cells from lipoaspirate remain 
positive for CD34 to nearly the same percentage as freshly isolated cells while cells from 
excised tissue show a significant reduction (p<0.05) (Table 5). The missing reduction in 
CD34 after cell adherence in liposuction material is surprising and the cause of this still is 
under investigation. Endothelial surface characteristics, such as CD31 and CD51/61, how-
ever, decrease during culturing (Table 5) in all conditions, which might be due to selection 
effects from culture medium as well as lower proliferation capacity of CD31+ SVF cells. CD31 
expression in Figure 15 A. appears rather homogenous compared to Figure 15 B., however, 
this is due to the two different preparation methods. In Figure 15 A., excised fat lobules were 
carefully isolated to only gain preadipocytes. Since this is macroscopically not possible, there 
is a very small but homogenous fraction of endothelial cells displaying CD31 characteristics. 
The presence of these two cell fractions causes a double-peaked flow cytometry curve. In 
Figure 15 B., liposuction material was used, which contains a much higher amount of endo-
thelials cells due to its origin and the method of yield which generates the two-peak appear-
ance of the flow cytometry. 
KDR expression in liposuction material is initially 43% ± 23% and decreases to 23% ± 7%, 
perhaps due to culturing conditions. This is in accordance with the reduction of endothelial 
markers. In excised adipose tissue, however, the findings of KDR expression remain contro-
versial since KDR expression immediately after isolation is surprisingly low and its increase 
due to cultivation is not in agreement with liposuction results (Table 5). 
In general stem cell markers (CD34, KDR and S100) on SVF cells decrease during long-term 
culture in standard medium as demonstrated in Figure 16. This is in agreement with the find-
ing that preadipocytes loose their differentiation capacity after multiple passages. 
To analyze CD31+ and CD31- differentiation characteristics and surface markers independ-
ently, unpurified SVF cells from excised adipose tissue were split by CD31 Dynabeads. Al-
ternatively, CD31 MicroBeads were applied for the cell separation if double-labeling was per-
formed.  
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Whether or not Dynabead attachment to the cell surface influences the differentiation poten-
tial of preadipocytes has not been analyzed so far. In order to minimize any impact of the 
Dynabeads, concentration of beads was kept low to allow proper attachment of cells to cul-
ture dishes which is otherwise impaired. As Dynabeads might bind non-specifically to adher-
ent and phagocytic cells, all steps with Dynabeads were carried out at 4°C. At this tempera-
ture, cell activity is low and non-specific binding reduced to a minimum. To further minimize 
non-specific binding, the bead-cell suspension was pipetted a few times after incubation 
(prior to separation on the magnet) to loosen any non-target cells adhering to the beads. All 
these procedures reduced non-specific binding of Dynabeads which was finally evaluated by 
staining Dynabead-carrying cells for vWF to ensure the endothelial phenotype. Cell counting 
with fluorescence and light microscopy revealed that 95 ± 5% of the cells carried Dynabeads 
(Figure 18 F.-I.). Of this fraction, 97 ± 2% were positive for vWF. This is supported by flow 
cytometry after MicroBead cell sorting (Figure 18 M.-N.). These results reveal the beneficial 
effects of the above shown technical modifications in Dynabead usage and show that 92 ± 
4% of CD31+ cells are vWF positive. Together with the high expression of CD105 in CD31+ 
cells (Figure 18 K.-L.), this confirms the mature endothelial cell phenotype and the unique-
ness of the CD31+ fraction. 
Freshly harvested CD31- SVF cells, in contrast to CD31+ cells, show no expression of vWF 
and CD31 as ECs would do, neither after one nor after two weeks of culture in proliferation 
medium (data not shown). Furthermore, CD31- cells do not present endothelial network for-
mation on plastic culture dishes (Figure 18 C.). Flow cytometry analyses reveal that this cell 
fraction is 100% positive for S100 (Figure 18 D.-E.). Even though S100 labels nervous tis-
sue, skeletal and cardiac muscle, malignant melanoma cells and some other cell types, it is 
well accepted as an early marker of adipogenesis21. It can therefore be assumed that the 
CD31- fraction consists of adipocytes in a precursor state, the original preadipocytes. Thus, 
separation of SVF cells by CD31 Dynabeads generates one cell fraction with preadipocyte 
characteristics (CD31-) and one with endothelial properties (CD31+). SVF cells have recently 
been shown to dedifferentiate from mature fat cells into a progenitor cell type and to differen-
tiate from there into ECs314. This has high implications for angiogenesis-related and cardio-
vascular topics. 
In conclusion the surface protein expression of SVF cells demonstrates characteristics of 
hematopoietic stem cells, early adipogenesis, ECs and endothelial progenitor cells (see Fig-
ure 24). 
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ADAS CELL DIFFERENTIATION TOWARDS ENDOTHELIAL CELLS 
SVF cells have the capacity to differentiate into multiple cell phenotypes including all three 
germ sheet lineages as mentioned earlier2,55,69,84,107,291,314,433,434. In addition to the remarkable 
differentiation capacity of SVF cells, these cells have recently been differentiated into an en-
dothelial phenotype when cultured under EC conditions60,260,314. The first study demonstrating 
the capacity of SVF cells to differentiate into capillary-like structures was already accom-
plished in 1999 by Zangani et al.429. When cultured on reconstituted basement membrane 
(RBM) from Engelbreth-Holm-Swarm mouse sarcoma, mammary stromal cells rapidly turned 
into capillary structures containing an internal lumen. The network formation was intensified 
by VEGF supplementation and inhibited by the anti-angiogenic agent suramin. Differentiated 
mammary stromal cells expressed KDR as well as ZO-1, a tight-junction-associated protein. 
Conversion into mature adipocytes was still possible when cultured under adipogenic condi-
tions. More recent studies used other ECM components than RBM, such as methylcellulose 
or Matrigel Extracellular Matrix as well as the presence of VEGF in combination with miscel-
laneous other growth factors for the differentiation of ADAS cells into ECs. When cultured in 
the presence of ECM proteins and VEGF, ADAS cells develop branched tubular structures 
and express various EC markers, such as CD31, CD34, vWF, CD144, and eNOS60,260,314. 
The differentiation of mesenchymal stem cells into mature ECs has great impact on clinical 
applications as well as tissue engineering research, as diffusion can supply cells just over a 
distance of about 150 µm with nutrition, which is insufficient in ischemic disease and also in 
larger three-dimensional fat tissue constructs in tissue engineering26. New capillaries from 
the surrounding tissue invade after a delay of about five days and are not able to reach the 
Figure 24. Cluster of 
Differentiation com-
parable to bone 
marrow stem cells 
Freshly isolated SVF 
cells have nearly the 
same surface character-
istics as stem cells 
from bone marrow and 
display mesenchymal 
stem cells. 
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centre of the construct. This leads to cell necrosis especially in highly vascularized tissues 
like adipose tissue31. 
 
THERAPEUTIC ANGIOGENESIS 
In 2004, Planard-Bernard et al. demonstrated a common origin for adipose tissue and endo-
thelium314. They postulated that adipocytes and ECs have a common progenitor; however, 
the interlinking pathways between adipose tissue and endothelium and the differentiation 
potential from one tissue into the other via progenitor cells have not been analyzed. So far it 
has only been shown that SVF cells are able to perform metaplasia from mature fat cells into 
endothelial cells314. This thesis focused on this concept and aimed to further analyze the 
interlinking pathways between adipose tissue and endothelium.  
ADAS cells show a remarkable potential to form capillary-like structures in vitro. Further, 
ADAS cells resemble EC characteristics in in vivo models as well. Angiogenic potential of fat 
tissue has been known and clinically applied for treating wounds and ischemic organs for 
more than 400 years (first mentioned in 1585)360,432. Applied for therapeutic angiogenesis, 
ADAS cells have a wide range of possible clinical applications in neovascularization266,380, 
including peripheral vascular disease, ischemic cardiomyopathy and myocardial infarction262, 
ischemic stroke193, diabetic retinopathy, acute tubular necrosis91,189 and transplant related 
ischemia. ADAS cells have first demonstrated enhanced angiogenesis and improved vascu-
larization in hindlimb ischemia models in mice60,260,266,274,275,314,325. Two potential but nonex-
clusive mechanisms could be involved in the pro-angiogenic effect of ADAS cells. Injected 
cells could directly contribute to incorporation into the vessel wall60,260,314, or cells release 
angiogenic growth factors which improve angiogenesis48,274,314. The interaction of both is 
most likely the cause for blood flow enhancement, increased capillary density, and improved 
angiogenesis induced by ADAS cells.  
To study the angiogenic potential of adipose tissue derived cells, Cao et al. used CD34- 
CD31- Flk-1+ cells60 that displayed features of EPCs. Miranville et al. applied CD34+ CD31- 
ADAS cells260. Most other studies utilised unpurified adipose mesenchymal stem 
cells274,314,325. Regardless of the applied subpopulation, all ADAS cell fractions improved an-
giogenesis, vascularization and blood flow, although CD34+ cells seem to be superior to 
CD34- cells in increasing capillary density in hindlimb ischemia260. CD34- cells induce CD34 
expression in ischemic tissue and vessels60 supporting the fact that CD34 is a crucial marker 
for neo- or revascularization. Administration of ADAS cells can potentially affect revasculari-
zation to a degree similar to the application of BMSCs260.  
A recent study has introduced a new method to approach decreased cardiac function after 
myocardial infarction with transplantation of  monolayered ADAS cells onto the scarred myo-
cardium four weeks after ischemic injury262. After application of ADAS cells with cell sheet 
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technology, the engrafted sheet gradually grew shaping a thick layer of tissue and compris-
ing freshly emerging blood vessels and a couple of cardiomyocytes. Additionally, angiogene-
sis was initiated in a paracrine manner and cardiac function improved subsequently in rats 
with myocardial infarction262. 
Another hint for the close relationship between adipose tissue and blood vessels is given by 
preadipocytes that transdifferentiate into smooth muscle cells (SMCs)1. By overexpression of 
aortic carboxypeptidase-like protein (ACLP) in adipogenic precursor cells a smooth muscle-
like cell phentotype can be induced in SVF cells and clonal preadipocyte cell lines1. ACLP is 
expressed in ECM components of collagen-rich tissues229 and is up-regulated during vascu-
lar SMC differentiation228. Under smooth muscle (SM) differentiation environment, with β-
mercapto-ethanol and ascorbic acid, preadipocytes express anti SM22a, SM myosin heavy 
chain, caldesmon, SM α-actin and develop stress fibers1.  
 
To further verify the theory on mesenchymal differentiation plasticity, we performed morpho-
logical studies on CD31- SVF cells seeded onto growth factor reduced Matrigel™ in different 
culture media, EC-2 or EC-3, respectively. EC-2 and EC-3 were chosen according to Study 3 
as these two media showed the best results in inducing endothelial cell morphology in SVF 
cells. The first medium (EC-2) is a culture medium to induce differentiation towards endothe-
lial lineage260. The second culture medium (EC-3) used has been applied as a hematopoietic 
and endothelial progenitor cell medium for peripheral blood progenitors125. CD31- cells, which 
were initially 100% positive S100 (compare Figure 18 D.-E.), were able to form three-
dimensional tube like structures in both media (Figure 19 A.-D.). EC-2 medium additionally 
allowed the formation of extensive intercellular tube networks (Figure 19 C.-D.). HUVECs 
used as a positive control also formed networks but were not able to form three-dimensional 
capillary-like structures (Figure 19 E.-F., compare to Figure 19 C.). Analyzing endothelial 
differentiation of CD31- cells grown in EC-2 or EC-3 by flow cytometry, we found that in EC-3 
medium CD31- SVF cells express CD34 up to around 40% and KDR of 80% (Figure 20 A., 
Table 6). EC-3 medium therefore seems to support endothelial precursor characteristics in 
the CD31- cells. In EC-2 medium, in contrast, CD34 and KDR expression was significantly 
lower (Figure 20 B., Table 6) demonstrating the capacity of this medium to enhance endothe-
lial differentiation to mature ECs and diminish endothelial precursor cell characteristics of 
SVF cells. In both media cells were positively stained for acLDL confirming differentiation 
towards an endothelial phenotype (Figure 20, Table 6). AcLDL labels endothelial progenitor 
cells, vascular endothelial cells, and macrophages. 
 
Adipose tissue contains a subtype of mesenchymal stem cells that owes the ability to differ-
entiate into mature ECs in vitro, migrate into peripheral blood vessels, enhance angiogenesis 
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and revascularization by differentiating into ECs in vivo. Cells with the same abilities derived 
from bone marrow as well as from blood circulation have been described since 199717 and 
were termed “endothelial progenitor cells” for their EC potential. EPCs from bone marrow are 
positive for CD34, VEGFR-2/KDR, CD133 and have the ability to take up 
acLDL17,74,125,171,181,301,333,397,398,424. During mobilization and subsequent blood circulation they 
lose CD133 and start expressing CD31, vascular endothelial cadherin, and vWF. Although 
most subpopulations of ADAS cells have unequal surface protein patterns, various unique 
markers were detected on them that resemble EPC characteristics. But not only the surface 
characteristics reveal similarities between EPCs und ADAS cells. ADAS cells seem to par-
ticipate in endothelial repair, neovascularisation and angiogenesis in almost the same man-
ner as EPCs. Indeed, ADAS cells and EPCs seem to be involved in the repair of damaged 
endothelium60,260,314. However, little is known about the signals associated in directing cells to 
the centre of injured endothelium. Both ADAS cells and EPCs are capable of transdifferentia-
tion into smooth muscle cells1,114 underlining the ability of vessel wall integration. EPCs may 
participate in remodelling of ischemic cardiac tissue and regeneration of ischemic myocar-
dium by modulation of angiogenesis and myogenesis190,205,215,348 in an almost comparable 
manner as ADAS cells262,373. 
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Figure 25. Vessel wall repair 
through EPCs and ADAS cells 
Similar to endothelial progenitor 
cells ADAS cells may take part 
in the repair of injured vessel 
walls. Some of the ADAS cells 
may integrate into the endothe-
lial monolayer after transdiffer-
entiation into endothelial and 
even smooth muscle cells. 
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Some research groups aimed to identify a cell population that exhibits EPC characteristics in 
adipose tissue. A recent study has isolated KDR positive cells from human lipoaspirates, 
enhanced KDR expression through incubation in a hematopoietic stem cell medium and sub-
sequently differentiated the KDR+ subpopulation towards the endothelial lineage252. The 
KDR+ subpopulation of LPA cells, pronounced as adipose EPCs, differentiated into ECs of 
about 95%, being positive for VE-cadherin, vWF, LDL-lectin and formed tubular structures. 
Although the KDR+ cells had striking characteristics of EPCs, an initial phenotyping and 
characterization of the EPC fraction (KDR+ cells) was not performed. Flow cytometry for this 
cell fraction was only performed for KDR alone, CD34, CD133 and acLDL uptake were not 
obtained. Therefore it remains questionable whether the KDR+ subpopulation contained adi-
pose derived EPCs.  
In another study, KDR+ ADAS cells were isolated and induced to perform endothelial lineage 
conversion by plain culturing in EC medium. Differentiated ECs expressed CD31, CD34, VE-
cadherin and eNOS and were capable of tubular structure formation on Matrigel extracellular 
matrix60. Even though the results so far display tremendous insights into the specific differen-
tiation potential of various cells, further investigations are needed to reveal the true potential 
of the different mesenchymal stem cell fractions from adipose tissue to undergo EPC differ-
entiation. 
 
ENDOTHELIAL CELL DIFFERENTIATION TO ADIPOCYTES 
CD31+ and CD31- were separately cultivated under adipogenic medium conditions to analyze 
their ability to convert into adipocytes. As expected, CD31- cells fully differentiated into ma-
ture adipocytes (Figure 22 A.-D.). Interestingly, purified SVF CD31+ cells also differentiated 
into mature adipocytes after 21 days under adipogenic culture conditions. As can be seen 
from Figure 22 E.-G., CD31+ preadipocytes and maturing adipocytes have CD31 Dynabeads 
attached to their cell membranes confirming their CD31 surface expression. Further they 
were positive for CD105 and vWF, additionally confirming their origin from endothelial line-
age (Figure 18 F.-N., Figure 26). While CD31+ and CD31- cells present a different morphol-
ogy during proliferation (compare Figure 22 A., 22 E.), they look identical in differentiated 
state as adipocytes (Figure 22 D., 22 H.). Numbers from microscopic cell counting well 
match with the more precise findings from GPDH assays in which CD31+ cells show a GPDH 
activity of 64% ± 11% compared to CD31- cells set 100% (Figure 23). Thus, these findings 
present for the first time a CD31+ progenitor cell type that can either convert into EC or adi-
pocyte, depending on the culture conditions (Figure 26). The CD31+ cell fraction is also 
CD34+, since CD34 was expressed by about 45% of cells in flow cytometry (Figure 18 O.-P.). 
The fact that CD34 and GPDH percentages do not completely match is due to the incongru-
ency between cell number (represented by CD34-level) and cell volume (GPDH-level). 
  
89
Preadipocytes
Adipose Tissue EC
Endothelial diff.
Adipogenic diff.
MatrigelTM
Adipogenic diff.
MatrigelTM
Endothelial diff.
CD31- S100+
CD31+ CD105+ vWF+
 
 
Figure 26. Morphological analysis of in vitro differentiation of CD31- and CD31+ adipose progenitor cells under 
endothelial and adipogenic differentiation conditions 
Adipose progenitor cells were separated by Dynabeads for ECs in a CD31- and CD31+ cell fraction, both fractions were inde-
pendently differentiated towards endothelial structures on Matrigel as well as towards mature adipocytes. 
 
 
In conclusion, the results presented here that adipose tissue is a source of mesenchymal 
progenitor cells with broad differentiation plasticity. It is not exclusively the CD31- S100+ cell 
population in adipose tissue, the classical preadipocytes, which can undergo fat differentia-
tion, but also the CD31+ CD105+ vWF+ cell fraction, phenotypically adipose tissue derived 
ECs (compare Figure 26). In turn, preadipocytes even though predetermined to naturally 
differentiate to adipocytes, have the potential to mature to endothelial network structures. 
Conclusively, the adipose SVF appears to be a pool of multipotent cells with high plasticity 
and differentiation capacity towards endothelium as well as adipose tissue. This might give 
rise to innovative strategies in further tissue engineering applications where the adipose SVF 
is applied for both, engineering of fat tissue and vascular structures. 
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ARTERIOSCLEROSIS AND ADIPOSE TISSUE 
Arteriosclerosis affects large and medium-sized muscular and elastic arteries. Pathological 
conditions, such as endothelial dysfunction, vascular inflammation, accumulation of lipids, 
cell death and calcification of the intima lead to an atherosclerotic plaque of the vessel wall 
(Figure 27). By protruding into the internal artery, plaques minimize the luminal diameter 
available for blood flow, which results in abnormalities of blood flow, vascular remodelling, 
acute and chronic obstruction and subsequent decreased oxygen supply.  
In the past atherosclerosis was seen as a bland lipid storage disorder, however, substantial 
advances in basic and experimental science have highlighted the role of inflammation as well 
as cellular and molecular components supporting plaque evolvement.  
Blood leukocytes, mediator cells of inflammation and host defence, play a major role in local-
ising the earliest lesions of arteriosclerosis and initiate the process of chronic plaque forma-
tion. Healthy endothelium does physiologically not allow leukocyte binding (Figure 27 A.). 
However, after endothelial injury at sites of shear stress in the circulation and atherogenic 
diet, inclusion of lipoproteins in the artery wall with accumulation of lipids in the subendothe-
lial space takes place (Figure 27 B.). Augmented expression of  selective surface adhesion 
molecules on arterial ECs promotes enhanced leukocyte recruitment237,273. When vascular 
endothelium becomes inflamed, increased expression of adhesion molecules as vascular cell 
adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) lead to bind-
ing of leukocytes to the activated ECs and integrins mediate firmer attachment (Figure 27 
C.). Further blood flow disturbance promotes production of proteoglycans in the vessel wall, 
that can bind lipoprotein particles, easing their oxidative modification and therefore advantag-
ing an inflammatory response234. Proinflammatory cytokines expressed within the artheroma 
provide a chemotactic stimulus to the adherent leukocyte and promote penetration into the 
intima. Infiltration of immune cells together with proteoglycan changes result in fatty streak 
accumulation. Certain inflammatory mediators (MCP-1, M-CSF) support expression of 
macrophage scavenger receptors, promoting the adhesion of circulating monocytes entering 
the intima. Monocytes convert into macrophages when taking up the modified lipoproteins 
located in the intima. These lipid-laden macrophages together with T-lymphocytes form a 
lipid core that is isolated from the blood flow by a fibrous cap generated by migrated 
SMCs371. Activated leukocytes and intrinsic arterial cells release mediators regulating this 
process, comprising growth factors and cytokines such as TGF-β, PDGF BB, TNF-α and -β 
and interferon-γ42,361. Fibrogenic growth factors stimulate SMC replication and the production 
of a dense ECM leading to a more advanced atherosclerotic lesion (Figure 27 D.)336. But 
inflammatory mediators can further evoke the expression of collagenase by foam cells in the 
intimal plaque which comprehends thinning of the fibrous cap, leaving it weak and suscepti-
ble to rupture. Final evolvement of the end-stage plaque implies also further accumulation of 
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inflammatory cells, specially macrophages and T-lymphocytes, apoptosis and necrosis of the 
central part of the lesion and calcification, resulting in evolvement of a necrotic core (Figure 
27 E.)371. Cross-talk between macrophages and T-lymphocytes heightens the expression of 
the potent pro-coagulant tissue factor238. When thinning of the fibrous cap and blood flow 
disturbance lead to plaque rupture, the tissue factor triggers fatal thrombus formation that 
causes arterial occlusion and a subsequent acute ischemic event of the target organ. 
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Figure 27. Stages of atheroscle-
rosis  
A. Healthy endothelium. Blood 
leukocytes adhere poorly to normal 
endothelium. B. Inclusion of lipo-
proteins in the artery wall  after 
biochemical injury and subsequent 
lipid accumulation. C. Leukocyte 
recruitment to the nascent athero-
sclerotic lesion. When the endothe-
lial monolayer becomes inflamed, it 
expresses adhesion molecules that 
bind leukocytes. Proinflammatory 
cytokines expressed within 
atheroma provide a chemotactic 
stimulus to the adherent leuko-
cytes, directing their migration into 
the intima. Inflammatory mediators 
can augment expression of macro-
phage scavenger receptors leading 
to uptake of modified lipoprotein 
particles and formation of lipid-
laden macrophages, foam cells. D. 
Lymphocytes join macrophages in 
the intima during lesion evolution. 
Leukocytes, together with resident 
vascular wall cells, secrete cyto-
kines and growth factors that can 
promote the migration and prolif-
eration of smooth muscle cells. E. 
Inflammatory factors can inhibit 
collagen synthesis and evoke the 
expression of collagenase by foam 
cells. These alterations thin the 
fibrous cap, leaving it fragile and 
susceptible to rupture. 
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Numerous studies suggest that adipose tissue may have a strong impact on most obesity-
related cardiovascular complications, since an interrelation between adipocyte secreted pro-
teins and insulin resistance, hypofibrinolysis, inflammation, thrombosis and artherosclerosis 
becomes more and more evident. Adipose tissue controls not only energy metabolism, but 
further displays a secretory tissue for adipocytokines, which modify vascular response, for 
proinflammatory cytokines, and for PAI-1, abetting fibrin accumulation. Most of these factors 
produced by AT illustrate a major clue in the evolvement of the metabolic syndrome in obe-
sity. The metabolic syndrome is defined as cumulative cooccurrence of visceral obesity, 
dyslipoproteinaemia with increased LDL and triglycerides but decreased high density lipopro-
tein (HDL) and essential hypertension. The beginning of metabolic syndrome is dominated 
by an insulin resistance of the insulin-dependent tissues and impaired glucose tolerance, 
requiring an increased insulin level for cellular glucose utilisation. This hyperinsulinaemia 
heightens the feeling of hunger, resulting in obesity and progression of atherosclerosis323. 
Recently, even more constituents of the metabolic syndrome have been revealed, compris-
ing subclinical inflammation, hyperuricaemia and microalbuminuria.  
Among the adipocytokines, leptin as well as adiponectin play a role in the development of 
cardiovascular risk factors. Leptin is a glycoprotein produced by mature adipocytes and acts 
as a central part in controlling body fat storage. As adipose mass increases, its plasma level 
increases as well, resulting in constricted appetite and enhanced energy expenditure. But the 
mechanism of leptin does not work as efficient as it should since obese subjects remain 
obese despite raised leptin concentration, possibly due to leptin resistance comparable to 
insulin resistance in obesity.  
Adiponectin is also secreted by adipocytes and correlates positively with insulin sensitivity 
levels. This supports a negative association with body weight as plasma levels decrease with 
the degree of insulin resistance413. Adiponectin acts as an anti-inflammatory and anti-
atherosclerosis adipokine and accumulates in an injured vessel wall by specifically binding to 
collagen type I, III and IV293. Further adiponectin plays a role as a scaffold of newly formed 
collagen in myocardial remodelling after ischaemic infarction182 and reduces the expression 
of adhesion molecules on endothelial including VCAM-1 and ICAM-1296, which allow initial 
leukocyte recruitment in atherosclerosis237,273. It inhibits TNF production by proliferation inhi-
bition of myelomonocytic lineages and mature macrophage functions425, reduces oxidized 
LDL-induced EC proliferation270, and suppresses macrophage conversion into foam cells295. 
Lower risk of myocardial infarction comes therefore together with high levels of circulating 
adiponectin, whereas subjects with atherosclerosis seem to have low adiponectin concentra-
tions217,278. In contrary, resistin produced by adipose tissue induces the expression of endo-
thelial adhesion molecules VCAM-1 and ICAM-1206,404. 
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THE IMPACT OF PROGENITOR CELLS IN ATHEROSCLEROSIS 
Besides the classical hypothesis of the atherosclerotic process recent research findings indi-
cate the involvement of stem and progenitor cells from the blood circulation in the develop-
ment of arteriosclerotic lesions. Progenitor cells were found to take part not only in endothe-
lial repair but also in smooth muscle cell accumulation in the vessel wall. In animal models 
the injection of EPCs or BMSCs resulted in an aggravation of atherosclerosis and unstable 
plaque evolvement126,426. Atherosclerosis turns out to be a pathological process initiated by 
endothelial cell death, for instance due to trauma, which is followed by EC replacement 
through progenitor cell aggregation. LDL can easily accumulate in the intima during the dif-
ferentiation of progenitor cells, a process which takes several days to weeks. Further blood 
mononuclear cells adhere to freshly differentiated ECs and migrate into the subendothelial 
space. Meanwhile, blood and resident progenitor cells harboured in the adventitia migrate 
into the intima, followed by proliferation and differentiation into SMCs. According to that pro-
genitor cells seem to be accountable for the formation of atherosclerotic lesions as a major 
cell source by giving rise to undue SMC accumulation172,173,347. In conclusion, stem cells 
seem not simply to participate in vascular repair, but further in atherosclerotic lesion forma-
tion via pathological remodelling of vessel walls183,250.  
Additionally Daub et al. proved that human CD34+ progenitor cells differentiate into foam 
cells and ECs through the regulation of platelets. A changed balance of platelet-mediated 
differentiation of CD34+ progenitor cells into foam cells and ECs may thus play a critical role 
in atherogenesis as well94.  
Taking these research findings and the differentiation plasticity of adipose SVF cells demon-
strated in this thesis, it might be possible that not only blood progenitor cells, such as EPCs, 
take part in atherosclerosis, but also progenitor cells from adipose tissue (compare Figure 
25).  
The broad differentiation plasticity of CD31+ SVF cells could be explained by the common 
mesenchymal origin of endothelium and adipose tissue and might have further implications 
on the pathogenesis of atherosclerosis. Previous literature findings link the development and 
advancement of atherosclerotic lesions to endothelial cells which are thought to be involved 
in LDL binding and metabolism391,400, thereby displaying adipocyte characteristics. The 
pathogenic processes in atherosclerosis might be not exclusively performed by endothelial or 
hematopoietic progenitor cells, but also in part by CD34+ adipose SVF cells as well as CD31+ 
cells showing adipocyte-related metabolic activities.  
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CONCLUSION 
 
This thesis demonstrates that the term “preadipocyte” can be misleading if purification by cell 
sorting or equivalent methods have not been applied. Depending on the method of yield the 
amount of endothelial cells in the SVF varies between 10% ± 2% in excised fat and 24% ± 
15% in lipoaspirate. The SVF is therefore not a unique cell fraction but a mixture of various 
cells with varying surface protein expressions, one of which is a CD31-, S100+ cell type which 
has the capacity to differentiate into adipocyte as well as endothelial precursor cell and ma-
ture EC, depending on the involved differentiation-inducing factors. In addition, the SVF fur-
ther contains a CD31+, CD34+, S100- cell fraction with an endothelial phenotype which can 
be converted into adipose tissue under adequate differentiation conditions. These results 
encourage new approaches in adipose tissue engineering, since the use of purified multipo-
tent SVF cells with adipogenic and angiogenic potential instead of applying the unpurified 
SVF cell pool might allow better vascularisation and tissue growth results. Furthermore, the 
findings of this thesis might have relevant impact on the pathogenesis of atherosclerosis 
since the development and advancement of atherosclerotic lesions seems to involve not only 
progenitor cells, but also endothelial cells displaying both, endothelial and adipogenic proper-
ties. 
 
 
Preadipocytes Adipose EC
Adipocytes Capillaries  
 
 
 
Figure 28. Plasticity of hu-
man stromal vascular cells to 
perform adipogenic and endo-
thelial differentiation  
Besides their natural branch of 
differentiation to fat cells and 
tubular structures, SVF preadi-
pocytes and endothelial cells can 
also differentiate into other 
phenotypes. Preadipocytes 
(CD31-, S100+) can form tubular 
structures on Matrigel, and 
endothelial cells (CD 31+, 
CD34+, S100-) can aquire a fat 
cell phenotype expressing fat-
specific enzymes. 
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